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ABSTRACT
CHARACTERIZATION OF MICROREACTOR AND ANALYSIS OF CARBONYL
COMPOUNDS IN EXHALED BREATH
Qi Li
November 19, 2018
Analysis of trace volatile organic compounds at parts per billion (ppbv) to parts per
trillion (pptv) level has become an important research frontier because of the applicability
for environmental monitoring and noninvasive diagnosis of diseases. The methods of
preconcentration for detection of trace aldehydes and ketones both in ambient air and
human exhaled breath have increased considerably over the last decade. However, the
majority of these methods are not efficient.
In this dissertation, we have improved an innovative microreactor that is suitable
for quantitative analysis of volatile carbonyl compounds (VOCs) in ambient air as well as
in human exhaled breath. The approach is based on microreactor chips fabricated from four
inch silicon wafers. The chips have thousands of micropillars in the microfluidic channels
for uniformly distributing gaseous samples flowing through the microreactors. The
surfaces of the micropillars are functionalized with a quaternary ammonium aminooxy salt
2-(aminooxy)-N,N,N-trimethylethanammonium (ATM) iodide for trapping trace ketones
and aldehydes by means of oximation reactions. ATM adducts and unreacted ATM are
v

eluted from the microreactor with methanol and directly analyzed by UHPLC-MS.
Design and characterization of the microreactors were first investigated. The
reaction kinetics of the aminooxy reagent ATM with carbonyl were obtained. A reactor
model was established to predicate the relationship between the capture efficiencies of
carbonyl compounds and the microreactor length at a given gaseous sample flow rate. The
microreactors were then used to study the stability of breath VOCs. VOCs, collected in
Tedlar bags, were stable for about two hours with less than 5% of a concentration decrease.
Storage of breath samples in a refrigerator reduces the concentration changes of VOCs.
The analysis of exhaled breath samples of patients for early lung cancer screening program
using the microreactor indicates that C3H6O, C2H4O2 and C4H8O2 can serve as biomarkers
to distinguish patients with pulmonary nodules from healthy controls. The analysis of
exhaled breath samples of the lung cancer (LC) patients, patients with benign pulmonary
nodules and healthy controls led to three VOCs (2-butanone, 3-hydroxy-2-butanone and 4hydroxy-2-nonenal (4-HNE)) as markers for distinguishing LC patients from patients with
benign pulmonary nodules and healthy controls. 4-HNE can also be used to distinguish
squamous cell carcinoma from adenocarcinoma LC.
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CHAPTER I

INTRODUCTION

1. Breath Analysis
Breath analysis is probably one of the oldest forms of disease diagnosis. Its usage for
disease diagnostics dates back to ancient Greeks where physicians used exhaled breath to
diagnose different diseases. 1,2 They already knew that the aroma of human exhaled breath

could provide clues to disease. Certain diseases have correct associations with breath. For
example, the fishy smell of breath associates to liver illness, a urine-like smell can accompany
failing kidneys, the diabetic patients often breathe a sweet smell due to the presence of acetone
in their breath, the grapes flavor of Pseudomonas infections, 3,4 or the sewer smell of the breath
of patients with lung abscesses, caused by the proliferation of anaerobic bacteria. 5-7

Both qualitative and quantitative methods for determination of chemical substances
in breath are included in breath analysis. In the 1970s, Linus Pauling detected (though
without identifying) around 200 different volatile organic compounds (VOCs) in exhaled
breath by gas chromatography. It was demonstrated that normal human breath is a gas
mixture with rather complex composition. In the last 30 years, researchers identified many

1

of these compounds. It has turned out that exhaled breath contains many VOCs, such as
acetone, methanol or isoprene and even small inorganic molecules like nitric oxide, carbon
monoxide or carbonyl sulfide. 8,9
Breath analysis provides a simple and convenient alternative to traditional medical
diagnostics in clinical laboratory, because it is non-invasive, painless, cost-effective and it
can be easily repeated. As we breathe out from our mouth, thousands of molecules are
expelled into the air. The composition of breath samples is often identified as a mixture of
volatile organic compounds (VOCs) (e.g., acetone, isoprene, ethane and pentane), simple
gases (e.g., NO, CO2, and CO), and even some non-volatile substances (e.g., isoprostanes,
peroxynitrite, cytokines).10 In addition to oxygen, nitrogen, carbon dioxide and water vapor,
human breath contains hundreds of volatile organic compounds (VOCs) whose
concentration variations may serve as biomarkers for specific diseases. It is recently proved
that there are approximately 3000 VOCs have been detected at least once in human breath,
and most breath samples usually contain more than 200 VOCs. Detailed analysis of their
composition can provide a diverse signature of physiological processes that took place in
the body (i.e. breath print) and along the pathways of ingestion or absorption since these
molecules have been produced from both endogenous and exogenous origins.5 If we can
capture and analyze this “breath print” correctly, it can be used to provide information of
the current health status with the potential to predict future outcomes. 11 In that sense, the
development of efficient devices that can be practically used for the analysis and
quantification of various volatile biomarkers in human breath has raised a huge interest in
recent years.

2

The potential advantages of breath analysis over other conventional medical tests
include that it is a totally non-invasive and painless method to assess a person’s health state,
the sampling method of breath analysis is very easy to operate as it does not need skilled
staff to operate and it can be used to people of all ages and conditions. In recent years,
breath analysis attracts a lot of attention due to the great potential in clinical diagnostics
and exposure assessment. 12
Biomarkers are quantifiable indications of physiologic function and disease activity
that provide a practical basis for diagnosis and monitoring of pathologic states.

13

In the

past years, researchers found some compounds can be used to define a disease in person.
For example, Corradi et al. found that malondialdehyde (MDA), heptanal and hexanal are
significantly increased in the EBC patients with COPD in comparison with nonsmoking
control subjects.14 Other compounds, such as nitric oxide, also be identified as a biomarker
of various respiratory diseases including COPD. Researchers reported that the
concentration of nitric oxide in COPD patients are consistently higher compared to healthy
controls.15-17 Table 1.1 lists physiological origins of some endogenous breath molecules. 18
Table 1.2 includes a summary of Lung Cancer-Related VOCs According to Recent
Literature.19 For example, the compounds and their possible endogenous sources.
Table 1. 1
Physiological origins of some endogenous breath molecules 18
Compound

Physiological basis

Acetaldehyde

Ethanol metabolism

Acetone

decarboxylation of acetoacetate

3

Ammonia

protein metabolism

Carbon sulfide

gut bacteria

Carbon monoxide

production catalyzed by heme oxygenase

Carbonyl sulfide

gut bacteria

Ethane

lipid peroxidation

Ethanol

gut bacteria

Ethylene

lipid peroxidation

hydrocarbons

lipid peroxidation/metabolism

Hydrogen

gut bacteria

Isoprene

cholesterol biosynthesis

Methane

gut bacteria

Methanethiol

methionine metabolism

Methanol

metabolism of fruit

Methylamine

protein metabolism

Nitric oxide

production catalyzed by nitric oxide
synthase

Pentane

lipid peroxidation

Table 1. 2
Lung Cancer-Related VOCs According to Recent Literature19
Compounds

Possible Endogenous
Source

Main Products
and/or Derivatives

4

Exogenous
Origin

Alkanes alkenes

Oxidative stress (PUFA
peroxidation)

Ethane, Pentane,
Heptane, Octane,
Decane,
Undecane,
Dodecane,
Nonadecane,
Isoprene, Propane,
Eicosane

Alcohols

Hydrocarbon
metabolism Absorbed
through GI tract

Propanol, Butanol, Natural, diet or
2-Ethyl-1-hexanol, disinfectants
Ethanol,
Methanol,
Heptadecanol

Aldehydes

Metabolism of alcohols
Lipid peroxidation

Propanal, Butanal,
Pentanal, Hexanal,
Heptanal, Octanal,
Nonanal,
Formaldehyde,
Acetaldehyde

Natural, diet or
waste products
Smoking

Ketones

Fatty acid oxidation
Protein metabolism

Acetone,
Butanone,
Pentanone,
Hexanone,
Heptanone,
Benzophenone,
Hendecanone

Natural, diet,
waste products
or
drugs/fragrance
s /paint

Carboxylic acids

Metabolism of amino
acids

Benzoic acid,
Propanoic acid,
Acetic acid

Food
preservatives,
solvents,
polymers

Esters

Metabolic pathway of
alcohols and acids

Ethanoate,
Propanoate,
Acetate

Fatty oils,
natural wax,
fruit essential
oils

Nitriles

---

Acetonitrile,
Azulencarbonitrile

Smoking

5

Natural, plastics
or petrol/fuels

Aromatic
compounds

---

Benzene, Toluene,
Styrene, 2,5Dimethylfuran,
Anthracene,
Dimethylnaphtale
ne

Petrol, smoking,
natural, tar, oil

2. Breath Sampling Methods
Exhaled breath sampling is one of the most important steps in breath analysis and
researchers should pay attention to a number of parameters, in order to avoid mistakes
when make assumptions about the origin of the compounds identified. These parameters
include the type and the number of breath collections, the portion of breath used, the breath
storage and the interference of environmental VOCs from the collection place. Breath
collection can be achieved through trapping a single breath or combining multiple breaths.
Both methods have associated advantages, which should be taken into account before
choosing one of the two. Overall, breath sampling is quick and simple, but the main concern
is that the sampling should be totally comfortable and safe to patients when they provide
exhaled breath. Since breath sampling can be performed easily, it allows large numbers of
subjects to be studied. Different research groups reported different sampling methods. For
example, the portion of breath being targeted can vary. The most usual techniques
employed in pre-concentrating VOCs in air and exhaled breath are sampling of the air of
breath in special recipients, collection in adsorbents as well as continuous sampling and
online analysis.
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2.1.Sampling
Several types of containers, such as gas tight syringes, glass bulbs, stainless steel
canisters and sampling bags, can be used for sampling and storing of breath samples.
Syringes and glass bulbs are cheap and easy to use and clean, but they are also fragile and
with a limited volume. Canisters (1000-3000 dm3) are made from stainless steel. The inner
surface of the canister is electropolished to minimize adsorption and losses of target
compounds. However, they are relatively heavy, bulky, expensive and require an effective
cleaning procedure for multiple use. Currently, Tedlar sampling bags (made from PVF,
polyvinyl fluoride) is one of the most commonly accepted materials for collecting gaseous
samples in general and especially breath gas samples.

20,21

PVF is considered chemically

inert to a wide range of compounds and adsorption of analyte molecules on its surface.
Tedlar bags also are cheaper and relatively good durability and reusability. Other polymer
bags such as Kynar, Flexfilm, Teflon (PTFE, polytetrafluoroethylene), Nalophan (PET,
polyethylene terephthalate) and metal-coated multilayer bags (Flexfoil and polyesteraluminum, PEA) are also used to store breath samples. Researchers have studied the
stabilities of selected breath constituents in these three types of polymer bags and they
found that the Tedlar bag has the best stability.
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Another important advantage is that

Tedlar bags can be reused for most applications, this will also save some experimental cost,
which may be important to researchers. Prior to reuse, the Tedlar bags must be evacuated
and thoroughly cleaned and flushed with purified air or nitrogen. When the Tedlar bags
are reused for analysis, it is recommended that this procedure be performed three to ensure
that the background levels are acceptable for use.
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Exhaled breath can also be sampled in its full composition (total breath sample or
mixed expiratory air) or, alternatively, only the alveolar air may be sampled. The first
choice has higher possibility to contaminations, since the sampling control is very deficient.
The patient just breathes for the sample collection bags and therefore the risk of
contamination with exogenous compounds from the oral cavity and dilutions in dead space
are higher and may compromises the analysis.
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These problems are reflected in the

variation of the number of compounds and their concentration. In contrast, alveolar air is
the part of exhaled air that has been in contact with blood inside alveoli. Dead space air
does not enter the gas exchange region of the lung, which includes mouth, nose, pharynx,
trachea and bronchi. 24
2.2.Metal containers-single breath canister (SBC)
In the 1990s, US Environmental Protection Agency (EPA) introduced the single
breath canister method of exhaled breath collection. Beginning with the Total Exposure
Assessment Methodology (TEAM) studies of the 1980s, EPA showed great interest in the
use of breath sampling as an exposure assessment technique. They studied a series of
population-based exposure assessment investigations designed to evaluate the most basic
aspects of pollutant exposure. In the study, breath and blood samples were collected from
volunteer subjects to determine which sampling technique would be most useful in
determining exposures. The sampling through this method was clean, noninvasive and
provided accurate information for many VOCs although this early method of exhaled
collection is cumbersome. 25
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This device comprised a stainless-steel canister that contained 1–1.6 L of alveolar
breath. With single breath canister (SBC), carbon dioxide was generally measured as 4.6%
of the exhaled breath, while the natural concentrations of isoprene and acetone served as
markers to ensure that the collected sample was alveolar breath.

26

In general, the device

was fitted with a Teflon tube for use as a mouth piece. 27 The subject was informed to close
their lips around the tube before exhaling and the valve remained open until the end of
expiration. An alveolar sample was obtained using the dead-space volume expelled before
the valve was opened. The SBC had the advantage that unlike other end-tidal breath
collection devices, these canisters are extremely durable and no special precautions are
needed when shipping samples back to the laboratory.

Figure 1.1 SUMMA Canister with disposable Teflon mouthpiece for sample collection.28
9

2.3.Sorbent tubes
Sorbent tubes are the most widely used collection media for sampling hazardous
gases and vapors in air, mostly as it relates to industrial hygiene. Sorbent tubes and traps
are widely used in combination with gas chromatographic analytical methods to monitor
the vapor-phase fraction of organic compounds in air. Figure 1.2 shows a detailed
description of commercial sorbent tubes which are commonly used recently.

Figure 1.2 A detailed description of sorbent tubes.29
2.4.Bio-VOC breath sampler
Recently, the Bio-VOCTM breath sampler, a commercial sampling device, has been
introduced and offers several advantages over the above techniques. A prototype of the
Bio-VOC breath sampler was developed by the Health and Safety Laboratory (Sheffield,
10

UK)30 and commercialized by Markes International (South Wales, UK). The Bio-VOC
breath sampler has three components: a mouthpiece, a volumetric sampler (tube/syringe)
that retains around 100 mL air, and a plunger. A subject breathes through a disposable
cardboard mouthpiece into the plastic Bio-VOC sampler, which has an open-end allowing
air to be displaced as exhalation proceeds. Figure 1.3 shows a photograph of the Bio-VOC
sampler with detailed information. As a result, the Bio-VOC sampler allows for the
collection of alveolar air, the last portion of the exhaled breath, which is more likely to
represent air from deep in the lungs. Once the breath collection is complete, the sampler is
capped and VOCs are concentrated using SPME fibers, inserted into the sampler,

31,32

or

on sorbent tubes, collected by discharging VOCs with a plunger onto tubed media. The
sorbent tubes are most commonly used. Figure 1.4 shows a photograph of a Bio-VOC
sampler, disposable mouthpiece, and sorbent tube. This device has now been used widely
in human exposure assessments because of its convenience.
A major limitation of the Bio-VOC sampler is the volume of the air collected. The
reported volume for the device ranges from 100 to 150 mL,33,34 which is much lower than
the volume collected with other sampling methods. However, no study has successfully
measured the actual volume of air collected using the Bio-VOC sampler. However, no
study has successfully measured the actual volume of air collected using the Bio-VOC
sampler.

11

Figure 1.3 (a) Photograph of the sampler; (b) cross-sectional diagram through the breath
sampler: ①mouth piece, ②outer ring, ③non-return valve, ④outer tube, ⑤adsorption
tube adaptor, ⑥Tenax adsorption tube, ⑦Tedlar bag, ⑧O-rings.35
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Figure 1.4 Photograph of a commercial Bio-VOC sampler, disposable mouthpiece, and
sorbent tube.36
2.5.Exhaled breath condensate (EBC)
Exhaled breath condensate (EBC) is formed through condensation of cooled
exhaled breath and has been analyzed for a variety of mediators, including hydrogen
peroxide, lipid mediators, purines, and cytokines. Exhaled breath condensate (EBC) is also
a promising source of biomarkers of lung disease. It is important to note that EBC is not a
biomarker, but rather a matrix in which biomarkers may be identified, in that way
equivalent to blood, sweat, tears, urine and saliva. EBC may be thought of either as a body
fluid or as a condensate of exhaled gas (and therefore not a body fluid). This issue is
relevant because of potential government regulatory issues involved with laboratory
assessment of “body fluids”.25
There are three principal contributors to EBC.37 The first is variable-sized particles
or droplets that are aerosolized from the airway lining fluid such particles presumably
reflecting the fluid itself. The second is distilled water that condenses from gas phase out
13

of the nearly water-saturated exhalate, substantially diluting the aerosolized airway lining
fluid. The third is water soluble volatiles that are exhaled and absorbed into the condensing
breath.
Exhaled breath condensate (EBC) has been proposed as a non-invasive means of
measuring airway inflammation. Unlike traditional methods of sampling secretions from
the lower respiratory tract such as bronchoalveolar lavage, EBC analysis has the advantage
of being simple to perform, may be repeated frequently, and can be applied to patients
during both the stable and exacerbation phase of disease. The condensate derives from
expired water vapor and volatile gases, but the presence of non-volatile solutes suggests
that droplets of airway lining fluid have also been collected due to aerosolization during
turbulent airflow. Analysis of these solutes may potentially provide insights into the
pathophysiology of lung diseases such as asthma,38,39 cystic fibrosis,40,41 and chronic
obstructive pulmonary disease.42,43
While exhaled breath condensate shows promise as a source for biomarkers in
pulmonary diseases, large variabilities in the concentration of solutes in EBC samples with
considerable overlap between normal subjects and disease groups have been reported.43
With absence of supporting data, much of the differences have been attributed to variations
in the proportion of water vapor diluting the airway lining fluid or variations in flow
affecting the amount of aerosolized solute.
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Figure 1.5 Schematic of apparatus and instrumentation for measurement of total exhaled
water and collection of exhaled breath condensate.44

Figure 1.5 shows a schematic of an apparatus and instrumentation for measurement
of total exhaled water and collection of exhaled breath condensate. 44 Subjects breathe
through a non-rebreathing two-way valve at a pattern set by the ventilation targeting system
which generates an audio visual feedback signal setting ventilatory rate and expiratory flow,
respectively. An air conditioning unit controls the temperature and moisture content of the
inspired air. Temperature and humidity sensors are located as shown. 44
Several options exist for collection of EBC samples. Multiple custom devices have
been used throughout the years, using various cooling techniques and device shapes and
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materials. In terms of parts-which are often found about a respiratory laboratory-such
homemade systems often can be made cheaply, although the expense in terms of personnel
time may be surprisingly substantial. Commercially available equipment is also available
as shown in Table 1.3. 45
The whole process of breath analysis contains sampling, pre-concentration,
measurement and data analysis as showed in Figure 1.6. So here we discussed different
sampling methods recently used, then different pre-concentration methods were introduced
following.
Table 1. 3
Commercially available exhaled breath condensate collection systems45
EBC
Manufacturer Advantages
collection
system

Disadvantages

ECoScre Viasys, USA,
en I and Europe
ECoScre
en II

Most commonly published EBC
collection system. More common
in European centers. Optional
package for determination of
total exhaled volume.

Not readily portable.
Cleaning
between
patients may need to be
extensive to abide by
standard
respiratory
care practices. No
ability
to
control
condensation
temperature (Eco1).

RTube

More total EBC collections
performed using RTube than
other
systems.
Multiple
collections can be performed
concurrently. More common in
North
American
centers.
Disposable (no cleaning between
patients). Portable. Can be
prepared for use in a standard
freezer.

Choice
and
maintenance of set
condensing temperature
requires
optional
cooling unit, otherwise
condensation
temperature is chosen
by
cooling
sleeve
preparation temperature
and
rises
during
collection.

Respiratory
Research,
USA
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Anacon

Biostec,
Spain

TurboDe
ccs

Italchil, Italy

Controllable temperature of Few publications
collection. Designed for use on
ventilated patients
Has both non-disposable and Few
publications.
disposable portions. Controllable Simple system. One
collection
temperature. collection at a time.
Moderately portable. Readily
cleanable because of disposable
components.

Figure 1.6 A diagram illustrating the off-line breath sampling pipeline.46
3. Preconcentration Techniques
As mentioned above, the concentrations of VOCs in exhaled breath are very low.
Therefore, small interfering compounds could affect the analytical results. To minimize this
interference, an intermediate step between sampling and analysis is sometimes necessary and
advantageous to increase the concentration level of the target analytes over the possible
interfering compounds. There are several concentration techniques available, such as cryogenic
17

trapping, usually used with the canister breath sampling, and adsorption in different thermal
desorption tubes (TD-tubes), sorbent traps and coated fibers. The adsorption option requires a
thermodesorption step, being usually followed by gas chromatography combined with mass
spectrometry (GC/MS). Commonly used pre-concentration methods include sorbent-

containing thermal desorption (TD) tubes, the employment of solid phase microextraction
(SPME), as well as needle trap devices (NTDs).
3.1.Thermal desorption (TD) tubes
TD tubes are popular for pre-concentration of VOCs and account for almost half of
the pre-concentration methods published to date. Sorbents can be manually packed into the
tubes or tubes can be purchased pre-packed from suppliers. Commonly used sorbents
include Tenax TA&GR, Carbograph 5TD, Carboxen. Due to the distinct properties of these
materials there is much variability in the range of volatiles that are trapped. Sample volume
should be considered in order to prevent breakthrough and subsequent loss of analytes.
Strong sorbents such as Carboxen are suitable for trapping very volatile organic
compounds(C2-C4) while Tenax sorbents trap less volatile VOCs in breath (C7-C15).

47

Whether to use single or multi-bed sorbents which will depend on analytes of interest, and
also the quantity of sorbent used.
When breath has been temporarily stored in polymer bags, VOC-capture proceeds
by attaching one end of the TD tube to the bag and the other end to a pump which functions
to pull gaseous breath from the bag across the sorbent. Although the use of these sorbentcontaining TD tubes is stated to be highly sensitive, it will cost a lot of time. Also, sorbents
like Carboxen are hydrophilic thus retain moisture which can negatively affect the
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quantitative capture of some analytes. Introducing a dry purging step especially when using
a hydrophilic sorbent may be a solution.
3.2.Solid phase microextraction (SPME)
Solid-phase microextraction (SPME) has been applied to the quantitative
determination of ethanol, acetone and isoprene in human breath. Solid-phase
microextraction (SPME), originally developed by Pawliszyn et al.,48,49 is a rapid,
inexpensive, and efficient technique for sampling solid, liquid, or gaseous samples. It
requires no solvents or complicated apparatus and provides linear results over a wide range
of analyte concentrations. Analysis of the extracts is performed using GC, GC/MS, or
HPLC. 48,49 In the SPME technique, a fused silica fiber coated with a polymeric stationary
phase is contained in a specially designed syringe whose needle protects the fiber when
septa are pierced. Figure 1.7 shows a SPME device modified for breath analysis. 49 The
fiber is directly exposed to a liquid or gaseous sample to extract and concentrate the
analytes. After the absorption equilibration is attained, the fiber is withdrawn into the
needle and introduced into an injector of a gas chromatograph, where the extracted
compounds are thermally desorbed and analyzed. SPME can be performed manually or by
an autosampler. The method is economical, because one single fiber can be used repeatedly.
Unlike in conventional methods for analysis of gaseous samples, modified equipment like
a complex valve injection system, a thermal desorption device, or a cooling trap is not
required by SPME. The SPME fiber is easily cleaned by desorbing any contaminants in a
hot GC injector. The SPME technique coupled with GC has been used to analyze volatile
and semivolatile air compounds. The fiber can be exposed directly to the air or to a sample
collected in a gas sampling bulb.
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Figure 1.7 SPME device modified for breath analysis.49
3.3. MEMS preconcentrator devices
Many efforts are being made to develop a microfabricated GC system (μGC) that
is small enough to be carried by individuals. A micro pre-concentrator (µPC) is a key
component in such a device. The µPC increases the concentration of analytes from low
concentration (e.g. parts-per-billion) to higher concentrations (e.g. parts per million) so that
low concentrations of analytes can be detected. 50 Micro-PCs, including a heated membrane
with a thin adsorbent layer, were developed by Frye-Mason et al. for detecting specific
chemical warfare agents. 51 Tian et al. developed a multiple-stage microfabricated PC with
a large adsorbent capacity.52,53
A new type of fully integrated MEMS µPC that has been fabricated and tested for
the rapid concentration of vapor species are introduced to a flame ionization detector (FID).
A one microliter size µPC filled with polyethyleneimine (PEI) coated microposts is
integrated with fast microvalves

54

(response time < 50 µs) and a resistive microheater

(ramping to 200 ºC in 0.5 seconds).55 The integrated PC can sample a cubic centimeter of
gas in 0.2 seconds with an 50 kPa inlet pressure, adsorb targeted species, heat and desorb
them in 0.5seconds, and inject the now concentrated gaseous species using fast acting
microvalves in pulses as small as 50 microseconds into separation columns in a µGC, or
directly into a detector. The unprecedented speed of this µPC (< 1 s) is enabled by MEMS
20

sizing and fabrication, allowing sniffing of phosphonates, toxic industrial compounds
(TICs), and other volatile compounds in seconds, rather than tens of minutes with
conventional systems. The micropost structures, which are subsequently coated with PEI,
are fabricated using deep reactive ion etching to achieve a high surface area-to-volume
ratio while permitting a relatively low pressure drop during the loading and injecting phases
of operation in order to reduce both power consumption and analysis time. 56

Figure 1.8 (a) A schematic cross-sectional diagram of the integrated preconcentrator
consisting of a NiCr microheater, a 1µL preconcentrator, and two microvalves. (b) Device
picture of the layers corresponding to (a).57
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Figure 1.8 shows a schematic diagram and device pictures of the integrated µPC. 57
It consists of a NiCr microheater, the posted preconcentrator cavity, and two electrostatic
microvalves. The NiCr microheater heats the silicon surface immediately adjacent to the
µPC to subsequently heat the gas and analyte up to 200 °C using a feedback control of
resistance-temperature relationships obtained in off-line calibration. The microvalves are
composed of a valve seating electrode, whose topside the µPC is integrated within, a
membrane electrode, and a valve opening electrode. The membrane electrodes located at
the inlet (A) and outlet (B) of the µPC, respectively, are opened by applying a voltage V1
and closed by applying V2, as shown in Figure 1.9. 57 This feature enables the injection
band width from the µPC to be controlled by the operation of the microvalves, rather than
by a slower desorption heating rate. Portable gas chromatographs or micro-gas
chromatographs (μ-GCs) provide an analytical tool that permits a quick analysis of volatile
organic compounds (VOC) for online monitoring. Figure 1.9 illustrates the (a) on and (b)
off operation of the microvalves, as well as important features contributing to a switching
performance on the order of microseconds. These features include pneumatically balanced
membranes (by P1), which is designed to have almost zero net pressure across the
membrane to handle increasing pressures, and center pads which are designed to increase
the electrostatic force between the membrane and the lower electrode.
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Figure 1.9 (a) A schematic diagram of the PC when the valves are opened, and (b) closed.57
The development of μ-GC system has driven an important research effort. Portable
gas chromatographs or micro-gas chromatographs (μ-GCs) provide an analytical tool that
permits a quick analysis of volatile organic compounds (VOC) for online monitoring.
Adding a preconcentration step should allow increasing the sensitivity of miniaturized
analyzer.58 The SRA Instruments Company developed and commercialized a MEMS gas
preconcentrator into a µ-GC module. Some research experiments conducted with a
preconcentrator filled with carbon nanopowder and compled to a micro chromatograph
have shown an accurate separation and identification of various trace VOCs within a gas
mixture.
The device developed by C. Pijolat et al.59 is a silicon microchannel (20 × 85 mm2,
thickness 500μm) obtained by deep reactive ion etching (DRIE) and designed with fluidic
micro-structures at the inlet/outlet leading to a preconcentration chamber with a volume of
14 μl. The microchannels were produced on a 5 Ω·cm, n-type, (100)-oriented 1mm µm-
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thick silicon wafers. The first step of the fabrication was the DRIE with a thick photoresist
used as an etching mask. Then the micro-channels were bonded with a PyrexR glass wafer
by anodic bonding. Finally capillaries were sealed at the inlet/outlet with ceramic cement
and a glass paste. The inlet/outlet has a depth of 500 µm, corresponding to the diameter of
the capillaries used as fluidics interconnections.59
The preconcentrator allows desorbing at relatively high temperature (230 °C) all
the molecules collected after an adsorption step made at ambient temperature thanks to an
adsorbent which is described. Figure 1.10 shows that on the backside of the silicon device,
a platinum resistance was screen printed to act as a heater with a heating rate of 40°C/min.
60

Figure 1.10 Design and schematic device composition; (a) platinum heater, (b) MEMS, (c)
glass cover, (d) capillaries.60
4. Analytical Methods
The detection and quantification of extraordinarily low concentrations of nonvolatile biomarkers/compounds in EBC requires highly sensitive analytical methods.
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During the last decade, separation methods have become the method of choice for the trace
analysis of various compounds contained in complex biological matrices.
4.1.Gas chromatography (GC)
The most popular method employed for the analysis of trace components in human
breath has been GC or its combination with flame ionization detection (FID), MS, or ionmobility spectrometry (IMS). In fact, almost all the exhaled breath VOCs reported so far
have been identified and quantified using MS-based methods, most often GC-MS.61 GCMS is possibly the most common and comprehensive approach to characterize exhaled
breath volatile organic compounds. It allows the selective analysis of one or simultaneous
analysis of many compounds that may be in the range from ppb to ppt. The GC-MS
involves separation of volatilized samples in chromatographic column based on different
parameters, such as the boiling point of the sample components or polarity of the GC
column. GC-MS system ionizes the target ions, separate them by mass to-charge (m/z)
ratios and uses the resolved fragmentation patterns to quantify the amount of each specific
VOC in the sample. However, there are other detection systems that have been coupled to
GC for breath analysis, namely FID and IMS. In the FID detection system, VOCs are
burned in the FID, producing ions and electrons that can conduct the electric potential and
this information is used for detection and eventually quantification. The advantages of GCFID system are high sensitivity, large linear response range and low noise. However, the
GC-FID system also has disadvantage that the FID detector is mass sensitive and its
response is not altered significantly by changes in mobile-phase flow rate. In turn, in the
GC-IMS system, ions are separated according to their mobility as they travel through a
purified gas, in an electric field at the atmospheric pressure. The IMS detector is also
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selective, allowing the quantification of VOCs in the exhaled breath. Regardless of the
detection method used in a GC analysis, this approach presents, however, some drawbacks,
for example, the requirement for sample pre-treatment (sampling and pre-concentration).
Therefore, a GC analysis is only suitable for indirect sampling and not for real-time
analysis, also the GC analysis usually takes hours, a time-consuming process. Thus, the
important concerns inherent to the sample pre-treatment that need to be carefully addressed
to improve the quality of the data obtained in a GC analysis are analytes loss and
degradation, particularly of those of reactive or thermally labile metabolites, and possible
contaminations.62-65 Figure 1.11 shows that GC-MS chromatography has been also used
for the identification of metabolic end products including pentane, acetone, ethanol,
isoprene and other VOCs in normal human breath.

Figure 1.11 Normal human breath chromatogram of GC-MS.66
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4.2.Selected ion flow tube mass spectrometry (SIFT-MS)
Selected ion flow tube mass spectrometry (SIFT-MS) is a new analytical technique
for the real-time quantification of several trace gases simultaneously in air and breath. It
relies on chemical ionization of the trace gas molecules in air or breath samples introduced
into helium carrier gas using H3O+, NO+, and O2+ precursor ions. Reactions between the
precursor ions and trace gas molecules proceed for an accurately defined time, the
precursor and product ions being detected and counted by a downstream mass spectrometer,
thus effecting quantification. Absolute concentrations of trace gases in single exhaled
breath can be determined by SIFT-MS down to ppb levels, obviating sample collection and
calibration. Illustrative examples of SIFT-MS studies include (i) ethanol metabolism,
exogenous compounds, elevated acetone during ovulation and breath and urinary
headspace studies of metabolites; (ii) analysis of gases from combustion engines, animals
and their waste, and food; and (iii) urinary infection and the presence of tumors, the
influence of dialysis on breath ammonia, acetone, and isoprene, and acetaldehyde released
by cancer cells in vitro. Figure 1.12 shows the principle of the SIFT technique. 49 The ions
listed in the flow tube are the precursor ions (upstream) and examples of the product ions
(downstream). Other types of product ions are possible. 49
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Figure 1.12 A schematic of the SIFT used for the study of ion-molecule reactions. When
configured to measure trace gases in air or breath samples it becomes a SIFT-MS.
4.3.Proton transfer reaction mass spectrometry (PTR-MS)
PTR-MS is a relatively new technique developed by Lindinger et al.67,68 for use in
breath research, but very promising because it can deliver results in a real-time online
measurement, with high sensitivities for VOCs detection and quantification (up to the pptv
range). PTR-MS uses H3O+ ions for proton-transfer reactions with many common VOCs,
while having little to no reaction with the highly abundant atmospheric gases (N2, CO2 and
H2O) that compose more than 99% of exhaled breath.67,68 PTR-MS is advantageous for
complex gas mixtures (like breath samples), as it does not require pre-concentration and
separation of samples prior to analysis. The instrument also has very high sensitivity due
to the high intensity and relatively high purity of the primary H3O+ that allows the injection
of higher currents of reagent ions directly into the drift region without prior mass selection.
It is demonstrated that PTR-MS can be used to determine the concentrations of about 30
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VOCs at a sensitivity of a few tens of ppt level (in 2 min).68 PTR-MS is suitable for noninvasive, on-line observation of biochemical reactions in the human body. This type of
approach is demonstrated to offer some insights into metabolic processes that were
previously inaccessible. However, there are a few disadvantages of PTR-MS, for example,
the limit of detection and the number of compounds that can be simultaneously analyzed.
Further, it is also impossible to separate nominally isobaric VOCs using the classic PTRMS since these compounds all result in protonated molecules via proton transfer reactions
with H3O+.

69

According to Herbig et al.,70 in order to resolve individual phases, it is

necessary to have a minimum of 3 Hz of sampling frequency in an online breath analysis.
Thus, this trade-off between the signal-to-noise ratio (S/N) and the number of measured
m/z limits the number of compounds that can be simultaneously monitored and the
respective limit of detection (LOD) that can be obtained.
4.4.Electronic nose
Array-based gas sensors (“Electronic Nose”) now offer the potential of a robust
analytical approach to exhaled breath analysis for medical use. Electronic noses rely on
chemical vapor sensor arrays that respond to particular chemical characteristics of
individual molecules, such as VOCs. By analyzing the data obtained from the sensor arrays
using statistical or structural algorithms, we can discriminate and identify volatile patterns.
The advantages of electronic nose compared to other analytical methods for breath analysis
are revealed to be rapid, simple and promising for reducing the time and costs of an early
diagnosis of the investigated diseases.
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The most updated electronic nose system used for breath analysis is shown in
Figure 13. It is comprised of an array of six commercial chemical gas sensors: MQ-2, MQ3, MQ-9, MQ-135, MQ-137 and MQ-138.71 The selection of the gas sensors was based on
their sensitivity and selectivity towards different gaseous compounds that can be found in
the exhaled breath. In this system, the sensors’ limit of detection is sometimes below the
VOC’s concentration present in breath, so the use of a sensor array distinguishes between
the investigated diseases. Immediately after breath collection, the samples were transferred
to sensors chamber by pumping the content of each bag at a constant flow rate of
200mL/min. Each sensor underwent a reversible change in its electrical resistance upon
exposure to exhaled breath. During the experiment, a relative humidity sensor was used for
constantly monitoring this parameter. The total acquisition time for all sensor signals are 5
minutes. Data acquisition system was accomplished using a PCI-6221 and a DAQ interface
running on the computer for visualizing and saving the data provided by sensors. Figure
1.13 shows the experimental set-up of a e-nose system.

Figure 1.13 Experiment set-up of e-nose system equipped with data acquisition software
used in exhaled breath measurement.71
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5. Lung Cancer Biomarkers In Exhaled Breath
Table 1.4 shows a summary of lung cancer biomarkers researchers have found in
recent years. For examples, in 2014, Fu’s group used FT-ICR-MS method to detect the
carbonyl VOCs in exhaled breath of lung cancer patients and healthy controls. They found
that 4 different biomarkers can be used to distinguish the lung cancer patients from healthy
controls. They also define the cut off concentration range for the 4 biomarkers.77 In 2013,
Broza group using SPME/GC-MS method also found that 3 biomarkers for lung cancer
patients although they did not provide the cut off concentration range of these compounds.
Table 1. 4
Characterization of selected exhaled breath (EB) volatile organic compounds (VOCs)
reported in the literature
Author, Year

Disease

Detection
Method

Volatile Compounds

Concentration

Kischkel,
2010 72

Lung Cancer

SPME/GCMS

Isoprene
2-butanone
pentanal
Pentanal
Hexanal
Octanal
Nonanal
Decane
Nonane
3,6-dimethyldecane
Alkanes and
derivatives
Cyclohexane
Benzene derivatives
2-hexanone
3-heptanone
2,2,4-Trimethylhexane

0.095 nM
0.158 nM
0.436 nM
0.275 nM
1.208 nM
1.068 nM
8.433 nM
NG

Fuchs, 201073

SPMEGC/MS

Calderia,
201174

Asthma

GC-MS

Philips,
201275

Pulmonary
tuberculosis

GC/MS

Broza, 201376

Lung Cancer

SPME/GCMS
Sensors
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NG

NG

Fu, 201477

Zou, 201478

Lung Cancer

Lung Cancer

FT-ICRMS

GC/MS

2-butanone
2hydroxyacetaldehyde
3-hydroxy-2-butanone
4-hydrohexenal
Hexadecanal

1.78-8.38 nM

Hexylpentadecane

72-81.5ppb

Dodecane
Hexadecanal
Dec-1-ene
Octanal
C4H8O
4-HHE
C4H8O2
C2H4O2

NG

0.13-0.77 nM
0.23-1.13 nM
0.005-0.05 nM
< 2-10 ppb

Handa, 201479 Lung Cancer

IMS

Li, 201580

Lung Cancer

FT-ICRMS

Fernandes,
201581

Lung Cancer

GC/MS

Acetaldehyde
Isopropene

< 2-10 ppb
72-81.5ppb

Bouza, 201782

Oral Cancer

SPME/GCMS

Undecane
Octene
Decanal
benxaldehyde

NG

2.255 nM
0.00672 nM
0.1595 nM
0.3875 nM

6. Dissertation Organization
This dissertation includes six chapters. Chapter 1 provides a review of different
methods of detection and analysis of volatile organic compounds in exhaled breath.
Chapter 2 investigates different design of microreactors and characterizes them and the
kinetics studies of oximation reactions of the aminooxy reagent ATM. Chapter 3 studies
the stability of breath VOCs in Tedlar bags. Chapter 4 investigates exhaled breath samples
of the patients from Floyd Memorial Hospital and finds that C3H6O, C2H4O2 and C4H8O2
can serve as biomarkers to distinguish patients with pulmonary nodules from healthy
controls. Chapter 5 analyzes exhaled breath samples of the lung cancer patients, patients
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with benign pulmonary nodules and healthy volunteers and found three VOCs (2-butanone,
3-hydroxy-2-butanone and 4-hydroxy-2-nonenal (4-HNE)) to distinguish LC from patients
with benign pulmonary nodules and healthy controls. 4-HNE can also be used to
distinguish squamous cell carcinoma from adenocarcinoma LC. Chapter 6 provides a
summary of overall conclusions and future work for continuous research on this exciting
technology.
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CHAPTER II

CHARACTERIZATION OF MICROREACTOR FOR BREATH ANALYSIS

1. Introduction
In recent years, many studies have shown that certain ketones and aldehydes in
human breath could be used as biomarkers for noninvasive diagnosis of lung cancer. PTRMS and SIFT-MS detected ketones and aldehydes in human breath without any
preconcentration process.83-86 The most difficult part for PTR-MS and SIFT-MS, however,
was to identify compounds with certainty since several compounds overlaped on a specific
mass-to-charge ratio. Solid phase microextraction (SPME) with adsorbed O-2, 3,4,5,6(pentafluorobenzyl) hydroxylamine hydrochloride (PFBHA) has been used for analysis of
aldehydes in human breath. SPME was introduced as a rapid extraction technique for
analysis of volatile compounds from a variety of matrices and it was a popular
preconcentration method a decade ago. But the SPME method has one major disadvantage,
which is its small surface area for reaction. 87-91 The preconcentrators fabricated on silicon
wafers using microelectromechanical system (MEMS) technology typically consist of a
microhotplate and an adsorbent placed adjacent to the heating element. Physical adsorption
for preconcentration of trace VOCs and thermal desorption to release the adsorbed VOCs
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procedures were used for MEMS preconcentrators.10,11 However, MEMS-based
preconcentrators have low physical adsorption efficiency and poor selectivity issues. The
drawbacks for electronic nose are its low sensitivity and specificity for detecting lung
cancer. Exhaled breath condensate (EBC) provides a convenient and non-invasive method
for sampling of the airway lining fluid of the respiratory tract, but it is easy for volatilization
so it is hard to detect when operating. The exhaled breath is easy to degrade with analysis
time increasing, so the most important thing for improving accuracy is to decrease the
sample process time as short as possible.92-95
In this chapter, we describe a fabricated microreactor with custom-engineered
surface functionality for preconcentrating ketones and aldehydes in exhaled breath as
cationic derivatives through oximation reaction instead of physical adsorption. The
custom-engineered surface functionality was realized by adsorbing quaternary ammonium
aminooxy salt, 2-(aminooxy) ethyl-N, N, N-trimethylammonium iodide (ATM), on the
surfaces of micropillars in the microreactor. Then we use methanol flow through the
microreactor so that the entire trapped analytes can be eluted out and directly analyzed by
UHPLC-MS system. In order to decrease the time for analysis, we designed different
structures of microreactors. The width of the microreactors was unchanged. The difference
is the length; we set 7mm as a unit for length. Then we fabricated microreactors with
lengths of 7mm, 14mm, 21mm, 28mm, and 42mm. All microreactors were then tested for
capture of ketones and aldehydes. We also changed the air flow rate through the
microreactor to decrease the time for analysis. If we can get same capture efficiency in a
very fast flow rate with the longer microreactor compared to the microreactor with 7mm
in length with very slow flow rate, then this will be a significant improvement. After testing
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this, we use chemical reaction engineering theory to set up a model that can be used to
predict the effect of length and flow rate with capture efficiency.

2. Design and Fabrication
The design and fabrication process are referring to the procedures of the MEMS
device. The design contains 16 microreactors, and each microreactor has a microfluidic
channel that has micropillars of circular and triangular shapes. Figure 2.1 shows four screen
shots of the photomask design. Figures 2.1.a&b show the dimensions of the devices, the
channel is 7mm in width, 14mm and 21 mm in length. Figures 2.1.c&d show the design of
the circular and triangular micropillars. The circular micropillar has a diameter of 50 µm
and the gap between the pillars is 10 µm. Each side of the triangular micropillar is 50 µm
with 10 µm gap between the micropillars.
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Figure 2.1 (a) Layout for a microreactor with a channel of 14 mm long and 7 mm wide. (b)
Layout of microreactor with a channel of 21 mm long and 7 mm wide. (c) Layout of the
triangular micropillars. Each side of the triangular micropillar is 50 µm and the gap
between the adjacent triangles is 10 µm. (d) Layout of the circular micropillars. The
diameter is 50 µm and the gap between the micropillars is 10 µm. (e) Mask layout of 21mm
length microreactor.
Figure 2.2 illustrates the fabrication steps used to produce the microreactors. The
fabrication process was done in the cleanroom of the Micro/Nano Technology Center
(MNTC) at University of Louisville. The wafer used for the microreactor fabrication was
100mm in diameter, 1000 µm in thickness, <100> p type single side polished silicon wafer.
The resistivity of the wafer was 1-20 Ω-cm. The wafer was successively rinsed using
acetone, methanol and then deionized (DI) water, dried using a stream of pure N2 gas, and
then heated on a hot plate at 115 °C for 10 minutes before fabrication. Photoresist was
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patterned on the wafer using a photomask containing 16 microreactors. The microreactor
had microchannels that contained micropillars with circular and triangular shapes. These
micropillars were created by using Deep Reactive Ion Etching (DRIE). The micropillars
were thermally oxidized to form an oxidation layer with a thickness from 50 to 100 nm.
The last step was bonding the oxidized wafer with Pyrex glass wafer using an anodic wafer
bonding process. The bonded wafers were diced into separate microreactors. Fused silica
was connected to the ports created by the gap between the etched inlet and outlet and the
pyrex glass.

Figure 2.2 Fabrication process to create the microreactors. (A) Bare silicon wafer. (B)
Photoresist patterning using UV exposure. (C) Photoresist development using MF319. (D)
Micropillars formation using Deep Reactive Ion Etching. (E) Thermal oxidation of
thickness 50 nm to 100 nm. (F) Anodic bonding of Pyrex glass and the oxidized wafer.
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Details of the fabrication steps are as follows.
2.1 Photoresist patterning
A positive photoresist MEGAPOSIT® SPR ® 220 7.0 was coated on the prepared
silicon wafer at a spin speed of 500 RPM for 1 second and a spread speed of 4000 RPM
for 30 seconds. The wafer is soft baked at 115°C for 2 minutes. After exposing to the UV
source for 55 seconds exposure at 12W/cm2 through a photomask on a Karl Suss contact
aligner, the wafer is developed in MF319 solution for 90 seconds. The wafer is observed
under optical microscope to check whether the patterns are of channel and pillar arrays
match the photo mask. If not, the wafer is washed by acetone, methanol and DI water to
remove the residual photoresist, blew dry by pure N2, heat up at 115°C for 2 minutes and
redo the photolithography process. After development, the wafer is hard baked at 115°C
for 5 minutes. The hard-baked photoresist was used as a protective mask during the etching
process. Figure 2.3 shows the microscopic images of the micropillars. The photoresist
thickness, measured by the Dektak profilometer, at the center of the wafer was 6 µm.

(a)

(b)

Figure 2.3 Microscopic images of a) triangular and b) circular micropillars after the
photolithography step.
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2.2 Silicon etching using deep reactive ion etching
The 370±10 µm height micropillars in the microreactor channel were defined by
deep reactive ion etching (DRIE) using STS silicon DRIE machine. The gases used were
Sulfur Hexoflouride (SF6) and Oxygen (O2). The plasma was generated using R.F. signal
of frequency 13.56 MHz and power of 800 Watts. The etching time was 83 minutes. The
depth of the channel and the height of the micropillars are checked using profilometer. The
wafers were put in N-Methyl-2-pyrrolidone (NMP) bath to strip the photoresist followed
by oxygen plasma in the March RIE etcher for 1 minute to completely remove any
photoresist residues at a condition of 300 watts, Pressure 300 mTorr O2 flow (20% sccm).
Figure 2.4 shows the optical images of the devices were taken using a stereo microscope
after the etching process. Figure 2.5 shows the SEM pictures of different shape micropillars.

Figure 2.4 Optical images of the devices using stereo microscope.
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Figure 2.5 SEM images of the cylindrical, diamond, square and triangular shape
micropillars.
2.3 Thermal oxidation
The wafer is oxidized to form a 50 nm SiO2 layer on the micropillar surfaces in a
“wet” O2 and H2O atmosphere in a thermal oxidation furnace at 1000°C for 12 minutes.
The oxide layer thickness was measured using a FILMETRICS system.
2.4 Bonding and dicing
The wafer was sealed by anodic bonding with a glass wafer using Suss bonder.
Subsequently, the wafer is diced and the connection ports are opened.
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2.5 Silica tube mounting
The inlet and outlet of the microreactor were connected with 360 µm O.D., 250 µm
I.D. deactivated fused silica tubes using 3MTM Scotch-WeldTM Instant Adhesive CA4.
Figure 2.6 shows the microreactor connected with silica tubes compared to a dime dollar.

Figure 2.6 The picture of 21mm length microreactor compared to a US ten-cent coin.

3. Materials and Setup
All reagents and solvents, including deuterated acetone (acetone-d6) (99.9%),
acetone (99%), 2-butanone (99%), 2-pentanone (99.5%), pentanal (99%), acetaldehyde
(98%), and methanol (99.9%), were purchased from Sigma-Aldrich. The quaternary
ammonium aminooxy compound ATM was synthesized by professor Nantz’s group at
University of Louisville using the literature procedure.137
The quaternary ammonium aminooxy salt, ATM was used as a “capture phase” by
coated to the micropillars to trap ketones and aldehydes via oximation reactions. Figure 2.7
shows that schematic illustration of oximation reaction of ATM to capture ketones and
42

aldehydes in the microreactor. The surface functionalization of the channels and
micropillars with 2-(aminooxy)-N,N, N-trimethylethanam-monium (ATM) iodide was
performed by infusion of ATM iodide in methanol solution of known concentration from
a 2mL vial into the microreactor from one connection port followed by evaporation of the
solvent under vacuum. The electrostatic binding of the cationic ATM on the surfaces of
the micropillars can be done by the slightly negative surface charge of the silicon oxide
micropillars. ATM reacts chemoselectively with trace carbonyl VOCs in exhaled breath by
means of oximation with high reactivity. This approach is suitable for quantitative analysis
of ketones and aldehydes in exhaled breath. For rapid analysis and identification of trace
VOC adducts in a microliter volume sample, UHPLC-MS system was used in the
experiment.

Figure 2.7 Schematic illustration of ATM oximation to capture ketones and aldehydes in
the microreactor.
Figure 2.8. Shows the illustration of the instrument set up. A microreactor is
connected to a Tedlar bag (Sigma-Aldrich, St. Louis, MO) which contains the air sample
from synthetic air in a cylinder. We can adjust the flow rate by using a mechanical needle
valve. The flow rate of the sample through the microreactor can be measured by a flow
meter. In these experiments, we use a flow meter to set different flow rates: 3.5mL/min,
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5mL/min, 7mL/min, 8mL/min, 10mL/min, 15mL/min and 20mL/min. The microreactor
was loaded 30μL ATM in methanol solution which is 1.5μmol in advance and dried in an
oven with 60 kpa vacuum and 50 °C over night.
Air and exhaled breath samples were collected in 1-L Tedlar bag. The detailed
protocol for collection of exhaled breath samples was approved by the Institutional Review
Board (IRB) at the University of Louisville. For the characterization of different types of
microreactors, 1-L N2 collected from a cylinder as carrier gas was infused into Tedlar bag.
Then use syringe to add 5μL standard solution to Tedlar bag. The 5μL standard solution
contains 5nmol of each acetaldehyde, pentanal, 2-butanone and 2-pentanone. For the flow
rate through the microreactor, we use flow meter to change the valve until the flow rate is
3.5ml/min. After preparing the samples, the Tedlar bags were collected to the inlet port of
the microreactor through one fused silica tube. The exit port of the microreactor was
connected to a vacuum pump through the other fused silica tube on the microreactor as
shown in Figure 2.8. Then turn on the vacuum pump to pull gaseous sample from a Tedlar
bag through the ATM-coated microreactor. After evacuation, disconnect the microreactor.
Finally, the reacted ATM adduct and unreacted ATM are eluted from the microreactor by
flowing 150 μL methanol from one slightly pressurized vial through the microreactor and
then into an empty collecting sample vial. Figure 2.9 shows a process of elution. The eluted
solutions were directly used for UHPLC-MS analysis without any further process. A
known amount of deuterated acetone completely reacted with ATM (ATM-acetone-d6) in
methanol was added to the eluted solution as an internal reference (IR). The amount of
captured compounds was determined by comparing the UHPLC-MS signal abundance of
ATM-acetone-d6 with that of reacted ATM-ketone and ATM-aldehyde. The capture

44

percentage can be determined by dividing the amount of captured ketones or aldehydes by
the added amount of carbonyl compounds in the Tedlar bag. Then test the flow rate of
5mL/min, 7mL/min, 8mL/min, 10mL/min, 15mL/min and 20ml/min to obtain the capture
efficiency at different flow rates.

Figure 2.8 Schematic flow diagram of the evacuation process setup.

Figure 2.9 Elution of reacted ATM adducts and unreacted ATM from the microreactor.
4. Results and Discussion
Besides the flow rate effects on capture efficiency, we also designed experiments
to study whether the distance between micropillars and different pillar shapes affect capture
efficiency. For the pillar distance effect experiment, we designed 3 different distance
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micropillars, 10µm, 25µm and 50µm. We also designed the 4 different shapes micropillars,
triangle, circle, diamond and square shape.
1.5×10-6 mol of ATM in methanol was loaded into the microreactor and dried, then
5×10-9mol 2-pentanone, 2-butanone, acetaldehyde and pentanal dissolved in 5μL methanol
were injected into 1L Tedlar bag which contain 1L pure nitrogen. Then the samples were
evacuated through the microreactors under vacuum. After evacuation, ATM-carbonyl
adducts were eluted from the microreactors with 150 µl methanol to afford ≥ 99% recovery
of adducts. The eluted solution was analyzed by UHPLC-MS system. Figure 2.10 (a) shows
that for the microreactors with cylindrical micropillars, as the flow rate increases from 2.5
ml/min. The capture efficiencies of 2-butanone, 2-pentanone, acetaldehyde and pentanal
all are linearly decreased. Figure 2.10 (b) shows that as the gap between micropillars
decrease from 50µm to 10µm, the capture efficiencies of 2-butanone, 2-pentanone,
acetaldehyde and pentanal all are linearly increase. We also examined the micropillar shape
effect on the capture efficiency. Figure 2.10(c) show four different shapes of the
microreactors with the capture efficiencies. The shape of triangle has the highest capture
efficiency. After these experiments, we conclude that the smaller the micropillar distance,
the higher capture efficiency. High flow rate will decrease the capture efficiency and the
triangular shape micropillars can achieve the highest capture efficiency. After this study,
we find the optimal design of microreactors for capture trace ketones and aldehydes. So in
the following research, we designed optimized microreactors with the triangular shape of
micropillars and the distance between micropillars at 10μm.
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Figure 2. 10 (a): Relationship between capture efficiency and flow rate of the microreactors
with cylindrical micropillars, (the distance =10 µm, L=7mm). (b): Relationship between
capture efficiency and the distance at a flow rate of 5 ml/min. (Square, L=7mm), (c)
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Relationship between capture efficiency and the shapes of the micropillars (the distance d
=10 µm, flow rate=5 mL/min, L=7mm)
Although we found the optimal design of microreactors that have a high capability
to capture trace ketones and aldehydes in air and breath, there still exists a significant issue,
which is that the operating time is very long. Currently, the volume of the bag we use is 1L
and the flow rate experiment shows that high flow rate significantly decreases the capture
efficiency of the microreactors. In order to achieve higher than 90% capture efficiency, we
can only use a flow rate of 3.5 mL/min which means the time needed to evacuate the sample
is about 5 hours. This is a huge drawback. So our next target is to reduce the evacuation
time. There are two ways that we considered. One is to load more ATM into the
microreactor, and the other is to increase the flow rate but need to get the same capture
efficiency. For the first method, we use a 7mm length microreactor with triangle shape
micropillars and pillar distance 10 µm. 1× 10-6 mol ATM was loaded into microreactor as
a onetime loading, second set 1.5 × 10-6 mol ATM was loaded, third set 3× 10-6 mol ATM
was loaded into microreactor. 5 nmol acetaldehyde, pentanal, 2-butanone and 2-pentanone
dissolved in 5 µL methanol was injected into 1L Tedlar bag which filled with 1L pure
Nitrogen. Different capture efficiencies were achieved under different flow rate. Figure
2.11 shows that 4 different compounds capture efficiencies under different flow rate with
different ATM loading. The loading change almost has no effect on capture efficiencies of
all compounds. This is mostly because the concentration of ATM was much larger than
that of the compounds to be captured. In this case, we need to use the second way. For the
second way, we proposed a different design of microreactor with increasing the length of
the microreactor, this increase the numbers of micropillars inside the microreactor and also
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the residence time which make it possible to capture more carbonyl compounds in a short
time.
A designed microreactor with triangular micropillar shape and 10 μm distance
between micropillars was fabricated. The difference compared with the 7mm generation
chip is that the length is double, triple, 4 times and 6 times of the first generation chip. In
order to obtain higher capture efficiency with higher evacuation flow rate. 1.5 μmol of
ATM was loaded into the microreactor with 14mm length, 21mm length, 28mm length and
42mm length microreactor. 1L pure nitrogen was filled in Tedlar bags from a cylinder of
99.99% high purity nitrogen to evacuate through the microreactor by a vacuum pump. 5μL
mix standard solution (this 5μL solution contains 5nmol of Acetaldehyde, Acetone, 2butanone and Pentanal, respectively), was injected to the 1L nitrogen Tedlar bag. With the
fabricated microreactors, we start to characterize the microreactor with different flow rates.
Here we tested the flow rate of 3.5mL/min, 5mL/min, 7mL/min, 8mL/min, 10mL/min,
15mL/min and 20mL/min. After the evacuation process, ATM and its adducts were eluted
out of the microreactor with 200 µL methanol and the eluted solutions were then analyzed
by UHPLC-MS. The capture efficiencies at different flow rates were then obtained.
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Figure 2.11 Relationship between capture efficiency and flow rate of the microreactors
with cylindrical micropillars at different ATM loading; (a) Acetaldehyde, (b) pentanal, (c)
2-butanone and (d) 2-pentanone (the distance =10 µm, L=7mm).
Figure 2.12 shows that all the capture efficiencies decrease as the flow rate
increases. It is obvious that the microreactor with six times of the length (42 mm) of the
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first generation microreactors has the highest capture efficiencies compared to other design
of microreactors at the same flow rate. When the flow rate is less than 5mL/min, the
difference of the capture efficiencies among different length microreactors is very small
because at low flow rate, the capture efficiency already reaches above 95%. For the 4- and
6-times length microreactors, the capture efficiency is still above 95% even though the
flow rate is at 10 mL/min and the difference between these two length microreactor is small.
When the flow rate increases to higher than 10 mL/min, the capture efficiencies of all
microreactors decrease to below 90%. Therefore, the flow rate of 10 mL/min should be the
maximum flow rate that can be used for evacuation of exhaled breath samples. Now the
process time will only take one-third of the original process time which is a great progress
of this research. Previously we use the flow rate of 3.5mL/min to evacuate breath samples,
it will take about 6 hours to finish one 1L sample. For the one length (7mm) microreactor,
in order to achieve 95% capture efficiency, the flow rate needs to be lower than 3.5ml/min.
For 21mm length or longer length microreactor, the flow rate can increase up to 8 ml/min
with the same 95% capture efficiency. It is not always better to increase the length of
microreactor, one concern is that if the microreactor is too long, it will be hard to operate
during the process and it is not good for loading more ATM and eluting process due to
contamination and recovery of ATM adducts. Also the cost of fabrication will increase for
the longer microreactors. After considering the effect of operation, economic and practical
application, we conclude that 21mm length microreactors will be the best design for breath
analysis since it can achieve high capture efficiency at high flow rate (up to 8mL/min).
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Figure 2.12 The capture efficiency with different flow rate using different length of design
microreactors. (a) acetaldehyde (b) acetone (c) 2-butanone (d) pentanal.
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5. Modeling of the Microreactor
In the previous study, we found that the different length of microreactors can
achieve different capture efficiency under different flow rate of gaseous samples. Overall,
the longer microreactors can achieve higher capture efficiency. So, we finally choose to
use 21mm length microreactor for capture VOCs in order to balance the cost of wafer,
ATM loading and the capture efficiency. In order to further understand the relationship
between the capture efficiency and the length of the microreactors, we endeavor to
establish a model to predict the relationship between the flow rate and the capture
efficiencies of carbonyl compounds.
The microreactors are microliter-sized reactors that have thousands of vertical
micropillars which are coated with ATM on the surfaces. The air flows through the empty
area between micropillars and ATM captures VOCs by oximation reaction during this
process. So we simplify this microreactor as a packed bed reactor. Applying chemical
reaction theory, we can find whether this capture process is mass transfer-limited, or
reaction limited.
5.1 Kinetics study of oximation reaction in microreactor
In order to further design aminooxy salts for selective capture of some specific
carbonyl compounds, the reaction kinetics of aminooxy salts with ketones, aldehydes were
studied.
The whole experiment set up is the same as previous described, 21mm length
microreactor was used in this experiment. A constant amount of 1.5×10-6 mol ATM was
loaded into microreactor and dried in oven. 5×10-9 to 1×10-6 mol 2-butanone, acetone,
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acetaldehyde and pentanal dissolved in 5 µL methanol was injected into Tedlar bag which
filled with 500 mL pure nitrogen. The flow rate of gaseous samples was adjusted to
7mL/min by a flowmeter. Each experiment was operated under four different temperatures
(30°C, 50°C, 70°C and 90°C). The microreactor was eluted out with 200 µL methanol for
UHPLC-MS

analysis.

Different

conversions

were

measured

from

difference

concentrations of carbonyl compounds. Figure 2.13 shows that, as carbonyl concentration
increases, the conversion also increases. The conversion of acetone was higher than those
of 2-butanone, acetaldehyde and pentanal at the same carbonyl concentration while 2butanone conversion is higher than pentanal. These results also imply that the ATM
reaction rate with low molecular weight aldehydes may be greater than that with high
molecular weight aldehydes, same trend for ketones. These results may imply the
difference in reaction kinetics of carbonyls with ATM. The dependence of the ATMcarbonyl formation rate on the carbonyl concentrations is displayed in Figure 2.14. It is
clearly visible, how the reaction rate increased with the increase of the carbonyl
concentrations. Figure 2.14 shows that the curve of different carbonyl concentrations is
rather linear. Thus, it reveals that the carbonyl reaction order is close to one. In order to
figure out the exact reaction order of carbonyl reaction, the logarithm of the rate of
formation of ATM-Carbonyls as a function of the logarithms of the carbonyl
concentrations is plotted in Figure 2.15. It reveals the apparent reaction order for carbonyl
is 0.9024, which is very close to the first order reaction.
The volume of 21mm length microreactor is 0.0588mL, five different flow rates of
3.5 mL/min, 5 mL/min, 7mL/min, 10mL/min and 15mL/min was used for evacuating all
samples. 5×10-9 mol of 2-butanone, acetone, acetaldehyde and pentanal was injected into
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500 mL Tedlar bags, each sample was tested under 5 different flow rate and calculate
capture efficiency. (take 2-butanone as an example, if we consider the molecular flow
through the microreactor during the residence time which is effective reaction time
(t=1.008s for 3.5 mL/min flow rate), during this time, the ATM will capture some of the
molecular and some molecular escapes from the microreactor. When the 500 mL Tedlar
bad was fully evacuated, the capture amount of 2-butanone inside the microreactor was
calculated, the uncaptured amount escaped from the microreactor. The uncaptured amount
also accumulated from the time the gas flow through the microreactor. So at a very short
time, the volume of gaseous goes from the inlet of microreactor equals to that from outlet
port. The whole process of evacuation was accumulated by lots of residence time. So the
natural logarithm of the ration of concentration of inlet and outlet ln

𝐶𝑖𝑛𝑙𝑒𝑡
𝐶𝑜𝑢𝑡𝑙𝑒𝑡

can be

1

calculated byln( 1−𝐶𝐸 )) CE stands for capture efficiency.
𝐴𝑇𝑀 + 2 − 𝑏𝑢𝑡𝑎𝑛𝑜𝑛𝑒 → 𝐴𝑇𝑀 − 2 − 𝑏𝑢𝑡𝑎𝑛𝑜𝑛𝑒 + 𝐻2 𝑂

+

→

(1)

+

H2O

Scheme 1. A Scheme of ATM reacted with 2-butanone.

The reaction is first order for both ATM and carbonyl compounds. The molar
amount of ATM in the experiments is much larger than carbonyls (at least 100:1), ATM
concentration (amount) is considered as a constant and is included in the reaction constant
𝑘. Thus, the reaction rate (r) of 2-butanone with ATM is given as follow:
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𝑑𝐶2−𝑏𝑢𝑡𝑎𝑛𝑜𝑛𝑒
= −𝑘𝐶2−𝑏𝑢𝑡𝑎𝑛𝑜𝑛𝑒
𝑑𝑡

𝑟=

𝑑𝐶2−𝑏𝑢𝑡𝑎𝑛𝑜𝑛𝑒
𝐶2−𝑏𝑢𝑡𝑎𝑛𝑜𝑛𝑒

(2)

= -𝑘dt

(3)

Integrating with initial condition C=C0 at t=0, we have:
𝐶𝑖𝑛𝑙𝑒𝑡

ln

𝐶𝑜𝑢𝑡𝑙𝑒𝑡

=𝑘𝑡

(4)

The reaction rate constant 𝑘 can be obtained by linear regression between the
natural logarithm of the ratio of concentration of inlet and outlet ln

𝐶𝑖𝑛𝑙𝑒𝑡

, which can be

𝐶𝑜𝑢𝑡𝑙𝑒𝑡

calculated from the measured capture amount of compound, and the reaction time (t).
Figure 2.16 shows the regression plots between these two with 2-butanone.
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Figure 2.13 Relationship between carbonyls conversion and concentration.
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Figure 2.14 ATM-Carbonyls formation rate at different carbonyl concentrations.
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Figure 2.15 Determination of the reaction orders: the parity of the logarithm of the ATMCarbonyls formation rate and the logarithm of the carbonyl concentrations.
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Figure 2.16 Linear regression plots of lnCinlet/Coutlet vs t between ATM and 2-butanone
reactions at (a) 30°C, (b) 50°C, (c) 70°C, (d) 90°C.
From the regression plots, the slope the plot represents the 𝑘.
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From the Arrhenius Equation:
𝐸𝑎

𝑘 = 𝑘0 𝑒 −𝑅𝑇

(5)

where k is the rate constant of the reaction, k0 is the frequency factor, Ea is the activation
energy, T is the temperature (in kelvin), and R is the gas constant. We can obtain:
𝐸𝑎
1
𝑙𝑛𝑘 = − ( ) ∙ ( ) + 𝑙𝑛𝑘0
𝑅
𝑇

(6)

The activation energy and frequency factor were determined after linear regression
between the mean of ln(k) in four different reaction time at the same temperature and 1/T.
The reaction kinetics of acetone, 2-butanone, acetaldehyde and pentanal were
measured using the same procedures as that of acetone. Figure 2.17 shows the linear
regression plots of the natural logarithm of reaction constant (ln(k)) between ATM and
carbonyl compounds vs 1/T.
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Figure 2.17 Linear regression plots of ln(k) vs 1/T between ATM and carbonyl compounds
reactions. (a) Acetone, (b) 2-Butanone, (c) Acetaldehyde, (d) Pentanal.
Table 2.1 shows the activation energy and frequency factor of each reaction.
Table 2. 1
The activation energy, frequency factor, coefficient of determination of linear regression
and reaction constant in each reaction.
Ea(J/mol)

K0(S-1)

R2

K(S-1)

Acetone

315.22

3.496

0.954

3.1587

2-Butanone

279.41

3.487

0.9771

3.0827

Acetaldehyde

282.86

3.432

0.9657

3.1416

Pentanal

268.29

3.231

0.932

3.0107
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5.2 Modeling study of oximation reaction in microreactor
We simplify the microreactor as a packed bed reactor. In many packed bed
reactions, the overall rate of reaction is limited by the rate of mass transfer of reactants and
products between the bulk fluid and the catalytic surface. Mass transfer usually refers to
any process in which diffusion plays a role.
In this section we consider two limiting cases of diffusion and reaction in the
microreactor. In the first case the reaction is so rapid that the rate of diffusion of the reactant
to the surface limits the reaction rate. In the second case, the reaction is so slow that
virtually no concentration gradient exists in the gas phase.
In our microreactor model, the carbonyl compounds reaction is fast enough than
diffusion, we first consider this oximation reaction is mass transfer limited and we will
discuss the details information below. Under this circumstance the specific reaction rate
𝑘

constant is much greater than the mass transfer coefficient, 𝑘𝑟 »𝑘𝑐 , and 𝑘𝑐 «1, so
𝑟

-𝑟𝐴′′ =

𝑘𝑐 𝐶𝐴
1+𝑘𝑐 /𝑘𝑟

= 𝑘𝑐 𝐶𝐴

Figure 2.18 Diffusion across stagnant film surrounding catalyst pellet.
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The boundary condition at the external surface is

-rA″= WAr=kc (CA-CAs)

(7)

Where kc = mass transfer coefficient
CA = bulk concentration
CAs = concentration of A at the catalytic surface
According to the book ‘Elements of Chemical Reaction Engineering’,95 we have, for the
constant superficial velocity U, -U

𝑑𝐶𝐴
𝑑𝑧

+ rA″ ac=0

(8)

𝑑𝐶𝐴
Substituting for rA″in above equation, we have -U
𝑑𝑧

- kc ac (CA-CAs) = 0

(9)

In most mass transfer-limited reaction, the surface concentration is negligible with
respect to the bulk concentration (CA

» CAs), so -U

With the boundary condition at z=0, CA=

𝑑𝐶𝐴
𝑑𝑧

CA0, we get

= kc ac CA
𝐶𝐴

𝐶𝐴0

= exp (-

The concentration profile down a reactor of length L is shown in Figure

Figure 2.19 Axial concentration profile in a packed bed.
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(10)

𝑘𝑐 𝑎𝑐 𝑧
𝑈

)

(11)

𝐶𝐴0 −𝐶𝐴𝐿
The definition of conversion is X=
, with z=L use equation (11), we obtain ln
𝐶𝐴0
1
𝑘𝑐 𝑎𝑐 𝐿
=
1−𝑋
𝑈

Solve the equation, then we get X= 1- exp (-

𝑘𝑐 𝑎𝑐 𝐿
𝑈

)

(12)

Where ac is surface area per volume of pillar.
Since the microreactor has thousands of micropillars inside it. We can take one
of these pillars as a cell to study. the height of this cell is 400µm and the length of triangular
micropillar is 50µm. we calculate ac use following equation.

ac =

6(1−Ø)
𝑑𝑝

=

6×(1−0.3056)
9.388×10−5 m

= 44380 m2/m3

3

d = 3 6𝑉 √√3×6×400µ𝑚×(50µ𝑚)
=
p √

𝜋

2

4𝜋

=9.388×10-5m

2
2
Ø= 𝑉𝑣 =√3/4×60 ×400−√3/4×50 ×400=0.3056

𝑉𝑇

√3/4×602 ×400

(13)

(14)

(15)

Where A is surface area of the pellet, dp is particle diameter and Ø porosity.

The kc, mass transfer coefficient can be calculated by the equation of textbook
“Elements of Chemical Reaction Engineering, third edition”, the equation is
2/3

kc = 0.6×

𝐷𝐴𝐵

ʋ1/6

×

𝑈 1/2

(16)

1/2

𝑑𝑝

Since we use cylinder air as carrier gas, at room temperature and standard pressure,
the ʋ which is kinematic viscosity is 14.8×10-6 m2/s. We take 7mm length microreactor as
an example to calculate, the parameters of microreactor are 7mm length, 7mm length width
and 400µm depth of micropillars. For the flow rate of 7mL/min, we can convert to get the
velocity of flow is 0.417 m/s. Refer to Li L. etc paper96, the gas phase diffusivity (DAB) of
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2-butanone is 0.8×10-6 m2/s, Acetone is 0.85×10-6 m2/s, Acetaldehyde is 0.75×10-6 m2/s
and Pentanal is 0.78×10-6 m2/s. Then we can calculate kc for the reaction of 2-butanone
with ATM was determined to be 0.02255 m/s and the kc for acetone, acetaldehyde and
pentanal are 0.022817 m/s, 0.02059 m/s and 0.02013 m/s respectively. Then we plug kc
and ac into equation (12).
With equation (12), when we have the microreactor length and flow rate the air
flow through the micropillar, we can get capture efficiency of the microreactor. A plot of
different flow rate and capture efficiency of these different design microreactors was
showed below to describe the modeling results and the experimental results. A relatively
high matching trend was discovered. Figure 2.20 shows the 2-butanone experimental data
compared to model calculated data of the microreactors with 5 different lengths under
different flow. As clearly see from the figure, the model equation described the
experimental data almost equally except that at high flow rate (>15 ml/min), there is a
slight difference between experimental data and model data.
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Figure 2.20 Comparison of experimental data and the model simulation for capture
efficiencies of 2-Butanone using five different length microreactors.

Figure 2.21 shows that the 21mm length of microreactor’s experimental data
compared with simulated data at mass transfer limiting. As can be seen from the figure,
when the flow rate under 15 ml/min, the model shows a very fit to the experimental data.
Only when the flow rate at 20 ml/min, there is slightly different between the model data
and experimental data. These can be explained by the theory we discussed previously,
when the flow rate is high enough that the diffusion between carbonyls and ATM are fast
enough that the reaction between them dominate the whole process.
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Figure 2.21 Comparison of experimental data with the model simulation for capture
efficiencies of acetaldehyde, acetone, 2-butanone and pentanal with 21mm length
microreactor, (a) aldehydes, (b) ketones.
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When the reaction is slow and reaction rate limiting when mass transfer effects are
not important. When the specific reaction rate is small with respect to the mass transfer
𝑘

coefficient, 𝑘𝑐 »𝑘𝑟 , and 𝑘𝑐 »1, so
𝑟

-𝑟𝐴′′ =

𝑘𝑟 𝐶𝐴
1+𝑘𝑟 /𝑘𝑐

= 𝑘𝑟 𝐶𝐴

(17)

The 𝑘 (reaction constant) already calculated from the kinetic study when the
reaction is rate limiting, at room temperature, the 𝑘for 2-butanone is 3.0827 s-1, and the
𝑘for acetone, acetaldehyde and pentanal are 3.1587 s-1, 3.1416 s-1and 3.0107 s-1respectively.
In order to use model equation at reaction rate limiting, 𝑘𝑟 need to be calculated. By the
unit calculation of equation (7) and (17) we get the 𝑘𝑟 calculated by 1000 𝑘/ac. Then the
calculated 𝑘𝑟 of 2-butanone is 0.06946 m/s, and the 𝑘𝑟 for acetone, acetaldehyde and
pentanal are 0.07117 s-1, 0.07079 s-1and 0.06784 s-1respectively.
In order to further study the oximation reaction in the microreactor, we further plot
the ATM-carbonyls formation rate with U1/2. if the ATM-carbonyls formation rate (mol/s)
linearly to the U1/2, the reaction is mass transfer limited, otherwise, it is reaction limited.
Figure 2.22 shows the relationship between ATM-carbonyls formation rate and U1/2 with
7mm length microreactor and 42mm microreactor. As can clearly see from the figure, with
7mm length microreactor, at low flow rate (smaller than 10 mL/min), the ATM-carbonyls
formation rate is linearly to U1/2. At low velocities the mass transfer boundary layer
thickness is large and diffusion limits the reaction. As the velocity past the micropillars is
increased, the boundary layer thickness decreases and mass transfer across the boundary
layer no longer limits the rate of reaction, it is reaction limited. This data also demonstrates
that at low flow rate the reaction is mass transfer limited and when use calculated Kc for
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model equation, it shows a good fit with experimental data. When at high flow rate it is not
fitting to experimental data since it is reaction rate limited.
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Figure 2.22 Relationship ATM-Carbonyls formation rate with U1/2 with 21mm and
42mm length microreactor.
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6. Human Breath Analysis With Different Length Microreactors
After the modeling, the next step is the practical application of the microreactor for
human breath analysis. In this part, we collect 5L exhaled breath sample in one Tedlar bag
from healthy subjects, then separate each 5L breath sample into aliquots of 500 mL breath
samples. 7mm and 21mm length microreactors were prepared by loading 1.5×10-6 mol
ATM and drying in oven. Then the 7mm length microreactor was evacuated under a flow
rate of 3.5 ml/min while the 21mm length microreactors were evacuated under flow rate of
8ml/min and 10ml/min. The calculated capture amount of 7mm length microreactor at
3.5ml/min flow rate was set as a reference. For the captured amount of 21mm length
microreactors was compared to the 7mm length microreactor under 3.5 ml/min flow rate.
Figure 2.23 shows the capture amount of carbonyl VOCs in same exhaled breath in 3
different conditions. It is clearly seen from the figure that the 21mm-length microreactor
at a flow rate of 8 mL/min has a higher capture efficiency than that of the 7mm length
microreactor at 3.5 mL/min for all compounds. So we conclude that a 21mm length
microreactor can use at a flow rate of up to 8mL/min which can still have high capture
efficiency than 7mm length microreactor. This significantly decreases the analysis time by
more than half.
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Figure 2.23 Comparison of 7mm length microreactor capture and 21mm length
microreactor.
7. Conclusion
The results of this work show that a microreactor can be used to capture more than
95% carbonyl compounds in nitrogen. The microreactor is functionalized with the
quaternary ammonium aminooxy compound ATM for oximation reactions with ketones
and aldehydes. The advantages of thousands of micropillars in the microreactor include
increasing the contact surface area for gaseous sample flowing through the chip and
uniformly distribute gas flow to increase the chance of collision probability of ATM with
ketones and aldehydes in the gas phase flowing through the microreactor. After studying
the different design of microreactors with different length and micropillar shape, we find
the capture efficiency of microreactor increasing with the increase of length at the same
flow rate. When the length of the microreactor increases, the capture efficiency increases.
This indicates that increase of the surface area of the microreactor can improve the capture
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efficiency of it. But the increasing trend of capture efficiency will slow down when the
length was increased to a certain length like 21mm, when further increase to 28mm and
42mm, the capture efficiency is not a big difference compared to 21mm. The longer length
microreactor are hard to operate. Therefore considering all these aspects, the microreactor
with 21mm in length was recommended for future research of breath analysis.
A novel microreactor with 21mm in length was designed to efficiently capture
VOCs in human breath. With 21mm length microreactor, the flow rate can increase up to
8 ml/min which can still achieve 90% capture efficiency. This significantly decrease the
sample processing time compared to previous research. A theoretical model was developed
to predict the capture efficiency of the microreactor related to the microreactor length and
sample flow rate. The results of the model show a good prediction to the experimental data
at mass transfer limiting case.
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CHAPTER III

STABILITY OF BREATH VOLATILE ORGANIC COMPOUNDS IN TEDLAR BAGS

1. Introduction
The analysis of volatile organic compounds (VOCs) in exhaled breath is promising
for early detection of diseases including lung cancer and other cancers, diabetes,
Tuberculosis, cystic fibrosis, and nephropathy.98 Early detection of lung cancer is a key for
increasing survival rate of cancer patients.99, 100 Many studies have suggested that early
stage cancers can be detected by molecular analysis of VOCs in exhaled breath.101-106 More
than one thousand VOCs have been reported in human exhaled breath.107-109 In recent years,
exhaled breath has become a highly researched sampling medium for identifying specific
VOCs

as disease biomarkers for non-invasive diagnosis. However, due to trace

concentrations (ppbv to pptv) of VOCs in exhaled breath, these analytes require
preconcentration for quantitative analysis.120
Recent review papers report that gas chromatography (GC) coupled with mass
spectrometry (MS) is the most widely used system for analysis of VOCs in breath.111-113
Since there are hundreds of trace VOCs in exhaled breath, a preconcentration process is
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generally required to concentrate VOCs before they can be analyzed by GC-MS. There are
several methods that can be used for preconcentration. The most common preconcentration
methods are physical adsorption and thermal desorption using carbon-based adsorbents,
polymer adsorbents in tube or in needle, and solid-phase microextraction (SPME).114120

Proton transfer reaction mass spectrometry (PTR-MS) and selected ion flow tube mass

spectrometry (SIFT-MS) are also used for breath analysis without preconcentration
process.121-123 Other techniques including sensor array or electronic noses are also used for
analysis of VOCs in exhaled breath.124, 125
Although breath samples can be analyzed by many analytical instruments,
preservation of the sample integrity during sample storage and sampling process is critical
for reliable analysis of VOCs in breath samples.126-131 Tedlar bag is the most commonly
accepted materials for collecting breath samples.128, 130,131 The storage of selected VOCs
within sampling bags has been extensively studied.126-131 However, most of the previous
work studied VOC stability by spiking selected VOCs into air and nitrogen matrices. The
results indicate that the concentrations of VOCs in Tedlar bags decrease with time. Since
there is no publication studying the stability of real breath VOCs in Tedlar bags, it is still
not clear how long breath samples can be stored in Tedlar bags for standardizing breath
sample storage. The stability of real breath VOCs adsorbed on sorbents (Tenax TA and
carbograph) in tube samples has recently been studied.132-133,135
The objective of this study is to investigate the stabilities of breath VOCs in Tedlar
bags in order to identify appropriate storage time of breath samples at ambient temperature
and cold temperature (4 oC). A subset of VOCs named carbonyl compounds in exhaled
breath were measured because these compounds are very reactive. Furthermore, carbonyl
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compounds including 2-butanone, 3-hydroxy-2-butanone, hexanal, heptanal, nonanal,
hydroxy-acetaldehyde, 4-hydroxy-2-hexenal (4-HHE) and 4-hydroxy-2-nonenal (4-HNE)
have been reported as lung cancer biomarkers in exhaled breath.116-117, 134,136In this work, a
silicon microreactor approach was used to capture trace carbonyl compounds in exhaled
breath. Thousands of micropillars in the microreactors distribute gaseous breath flowing
through the microreactors and provide surface areas for trapping target VOCs. The surfaces
of the micropillars were functionalized by a quaternary ammonium aminooxy salt, 2(aminooxy)ethyl-N, N, N-trimethylammonium iodide (ATM), for chemoselective capture
of aldehydes and ketones via oximation reaction. The ATM-carbonyl adducts were
analyzed by a system of ultra high performance liquid chromatography-mass spectrometry
(UHPLC-MS).
2. Experimental
2.1 Materials
All reagents and solvents, including deuterated acetone (acetone-d6) (99.9%),
deuterated 2-butanone (2-butanone-d4) (99.9%), deuterated acetaldehyde (acetaldehyded4) (99.9%), deuterated hexanal (hexanal-d6) (99.9%), deuterated 2-pentanone (2pentanone-d5) (99.9%), acetone (99%), 2-butanone (99%), 2-pentanone and methanol
(99.9%), 5 Liter and 0.5 liter size Tedlar® bags were purchased from Sigma-Aldrich in St.
Louis, MO. The aminooxy-based reactive coating, 2-(aminooxy) ethyl-N, N, N
trimethylammonium iodide (ATM) was synthesized according to a published method.137
2.2 Microreactors
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The design and fabrication process of silicon microreactors follow standard MEMS
device fabrication procedures. A detailed description of the fabrication of the microreactors
has been published elsewhere. 139 The microreactors have been used for capturing carbonyl
compounds in environmental air and exhaled breath.140 The microreactor consists of
thousands of micropillars in an area of 21 mm in length and 7 mm in width. The
micropillars are equilateral triangular prisms with the side length of 50 µm and the height
of about 400 µm and the distance between two closest prisms are 10 µm. Figure 3.1 shows
a picture of the silicon microreactor chip and a SEM micrograph of the micropillar array.
The surfaces of the micropillars were functionalized with ATM by infusing a solution of
ATM (1.5µmol in 30µL) in methanol into the microreactor through one connection port
followed by evaporation of the solvent in a vacuum oven. Fused silica capillary tubes with
350 µm in O.D. and 250 µm in I.D. were connected to the inlet and outlet ports of the
microreactor with a bonding agent.

(a)
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(b)
Figure 3.1 (a) Optical picture of a microreactor with an insert of a SEM micrograph of the
triangular micropillar array at the top right corner; (b) the Schematic illustration of ATM
coating on the micropillar and oximation of ATM to capture carbonyl compounds.

2.3 Collection and analysis of exhaled breath samples
After approval by the Internal Review Board of the institution and after having
obtained written informed consent, exhaled breath samples were collected from 15 never
smoking and 7 current smoking healthy subjects. The Tedlar bags were cleaned with high
purity nitrogen and tested free of ketone and aldehyde contamination. Subjects directly
breathed about a mixture of 5 liter tidal and alveolar breath into five-liter size Tedlar bags
through the attached Teflon tube. A mixture of tidal and alveolar breath was collected in
the sampling bags. The breath samples from smokers were collected about 10 minutes after
smoking. After collection of breath samples, a number of 500 mL aliquots of the breath
samples were immediately transferred into 500 mL-size Tedlar bags. Then, 5 nmole of
each deuterated acetaldehyde, 2-butanone, hexanal, and 2-pentanone in 10 µL methanol
was added to the 500 mL breath aliquots. The breath aliquots were stored either at room
temperature or at 4 oC in a refrigerator before evacuation of the samples through the
78

microreactors. The first 500 mL aliquot was immediately evacuated through a microreactor.
The setup for evacuation of the breath samples to capture carbonyl VOCs includes a
vacuum pump to pull the gaseous breath from the Tedlar bag through the microreactor.139140

The sample bags were connected to the inlet of the microreactors through septa and

fused silica tube. The outlet of the microreactor was connected to a vacuum pump and the
flow rate of breath sample through the microreactor was adjusted to 7 mL/min. During the
evacuation process, carbonyl compounds react with the ATM coating and are trapped in
the microreactor while the rest of the breath sample flows through the microreactor. Figure
3.1 shows a schematic illustration of ATM coating on the surfaces of the micropillars and
the oximation reaction between ATM and carbonyl compounds. After a breath sample was
completely pulled through a microreactor, the microreactor chip was disconnected. Finally,
the reacted ATM adduct and unreacted ATM were eluted from the chip with 200 µL
methanol to afford ≥99% of recovered ATM-VOCs. An internal reference for UHPLCMS analysis was established by adding a solution of 5 × 10−9 mol of ATM-acetone-d6
adduct in methanol to each eluted solution. The eluted solutions were directly analyzed by
an ultra-high-performance liquid-chromatograph-mass spectrometry (MS) (UHPLC-MS)
system.
2.4 Ultra-high-performance liquid-chromatograph-mass spectrometry (UHPLC-MS)
A

Thermo

Scientific

ultra-high-performance

liquid-chromatograph-mass

spectrometry (MS) system equipped with an automatic sampler, a Vanquish UHPLC and
a Q Exactive Focus Obitrap Mass Spectrometer was used for analysis. The UHPLC column
compartment equipped with a Thermo Scientific Syncronis HILIC column (100 mm length,
2.1 mm I.D., 1.7 µm particle size). The liquid flow rate through the column was 600 µL/min.
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The column temperature stabilized at 30 °C with a total running time of 8 minutes. The
mobile phase A was ammonium formate and formic acid in methanol with a pH of 3.0 and
the mobile phase B was acetonitrile. The flow system consisted of 95% of phase A and 5%
of phase B. The injection volume of the sample was 10 µL.
3. Results and Discussion
3.1 Stability of spiked deuterated carbonyl compounds in breath samples
To determine both the capture efficiencies of carbonyl compounds by the
microreactors and the stability of VOCs in exhaled breath, deuterated acetaldehyde, 2butanone, 2-pentanone and hexanal were spiked into the breath samples and then stored at
4 oC in a refrigerator. The use of the microreactors with aminooxy coating for
chemoselective capture of trace carbonyl compounds via oximation reactions has been
established.137-138,93 Figure 3.2 shows that at time zero defined as immediately starting
evacuation of the breath samples after spiking the deuterated carbonyl compounds above
95% of these deuterated compounds were captured. Only less than 5% of each deuterated
compound lost due to reaction in the bags and escape from the microreactor during about
75 minutes of evacuation process. All of the spiked deuterated carbonyl compounds have
above 85% recovery after stored for two hours before starting evacuation of the samples
through the microreactors at room temperature. The recovery percentages of these
compounds for the samples stored at cold temperature (4 oC) are slightly higher than that
stored at room temperature. The spiked carbonyls in the breath samples decreased much
faster in the first 5 hours than after 5 hours stored both at room temperature and at cold
temperature. The two aldehydes and butanone decreased to about 80%, while pentanone
decreased to below 80% after stored for 5 hours at cold temperature. The recovery
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percentages of these deuterated compounds in breath samples of nonsmokers are slightly
higher than that in breath samples of smokers. Furthermore, the recovery percentages of
lighter acetaldehyde and butanone were higher than that of heavier hexanal and 2pentanone. This result is in good agreement with previous findings of higher molecular
masses with higher losses for the study of the stability of spiked volatile breath constituents
in Tedlar bags.128

(b)

(a)

Figure 3.2 Capture efficiencies of spiked four deuterated compounds in breath samples (15
Nonsmokers and 7 Smokers) with storage time at 4°C. The flow rate of breath sample
through the microreactor was 7ml/min. (a) deuterated acetaldehyde and hexanal, (b)
deuterated 2-butanone and 2-pentanone.
3.2 Stability of carbonyl compounds in exhaled breath of nonsmokers
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In order to compare the recovery percentages of carbonyl compounds in Tedlar
bags at different storage time and temperature, the amounts of breath carbonyl compounds
in 500 mL aliquots of all breath samples in Tedlar bags from 15 nonsmokers were
determined by evacuation through the microreactors and analyzed by UHPLC-MS in the
same way. Given the less than 5% of loss of spiked deuterated carbonyl compounds in
exhaled breath samples at time zero determined above, the measured amounts of carbonyl
compounds at time zero were set as reference for calculation of the recovery percentages
of the same compounds at the corresponding storage time both at room temperature and at
cold temperature. The stability of breath samples was examined as the recovery
percentages of each carbonyl compounds in the aliquots of the breath samples stored for
up to 24 hours.
Figure 3.3 shows the recovery percentages of ketones and aldehydes in exhaled
breath samples. The recovery percentages of all carbonyl compounds show the trends of
decreasing with storage time. The data also indicate that the samples stored at 4 oC have
higher recovery percentages than that stored at room temperature. The decreases of the
recovery percentages of carbonyl compounds in the first five hours are faster than that after
the first five hours. The recovery percentages of saturated carbonyl compounds are above
80% after storage for 5 hours at 4 oC. Hydroxyacetaldehyde degraded faster than
acetaldehyde while 3-hydroxy-2-butanone degraded faster than 2-butanone. Unsaturated
aldehydes including acrolein, crotonaldehyde, 4-hydroxy-hexenal and 4-hydroxy-nonenal
decrease to about 80% in 1 hour stored at cold temperature. Given the evacuation time of
75 minutes, the breath samples can be stored for a total of 2 hours to keep above 80%
unsaturated aldehydes at cold temperature. The obviously lower recovery percentages of
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unsaturated aldehydes in comparison with that of saturated hydroxy-carbonyl compounds
indicate that higher reactivity of these compounds is a key factor of the loss. The loss from
diffusion of the compounds through the films of the Tedlar bags is probably not important
because the recovery percentages of smaller and more volatile compounds such as
formaldehyde and acetaldehyde are higher than that of heavier compounds.
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Figure 3.3 Relationship between the residual percentage and storage time of four typical
carbonyl compounds under two conditions of storage: room temperature and cold
temperature (4°C) with 15 non-smokers’ breath samples (a) formaldehyde and
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acetaldehyde, (b) acetone and 2-butanone, (c) hydroxyacetaldehyde and 3-hydroxy-2butanone (d) acrolein and crotonaldehyde, (e) 4-HHE and 4-HNE.
3.3 Long term stability of carbonyl compounds in exhaled breath samples of
nonsmokers at low temperature
Since lower temperature can keep higher recovery percentages of breath VOCs in
Tedlar bags, long term stability of breath samples of the 15 nonsmokers was tested by
storing breath samples in refrigerator at 4 oC. The recovery percentages of carbonyl
compounds in breath aliquots were determined after 1, 2, 4, 7 and 14 days. Figure 3.4
shows a consistent trend of reduction in recovery percentages of ten breath carbonyl
compounds. While all saturated carbonyl compounds decreased to about 60% to 70% range,
unsaturated acrolein and crotonaldehyde decreased to about 39% and 4-HHE and 4-HNE
decreased to 30% after 24 hours. The very low concentrations and high reactivity of 4HHE and 4-HNE make it difficult to detect them by other methods. The recovery
percentages of lighter compounds are higher than that of heavier compounds. The fastest
decrease of the recovery percentages are 4-HHE and 4-HNE. This long-term stability study
indicates that breath samples can only be stored for a short period of time even at cold
temperature. In order to recover at least 80% of carbonyl VOCs for quantitative analysis,
breath samples in Tedlar bags will need to be stored at cold temperature and to be processed
or analyzed within 2 hours.
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Figure 3.4 Relationship between the recovery percentage and long term storage of
representative carbonyl compounds under refrigerated cold temperature storage (4°C) with
15 nonsmokers’ breath samples.
3.4 Stability of carbonyl compounds in exhaled breath of smokers at cold temperature
To investigate the stability of carbonyl compounds in exhaled breath of current
smokers at cold temperature and compare the stability difference with nonsmoker exhaled
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breath, seven breath samples of smokers were collected and stored in a refrigerator at 4 oC
for analysis. Figure 3.5 shows that the recovery percentages of all saturated carbonyl
compounds in breath samples of smokers were lower than that in nonsmoker breath
samples which is consistent with the stability of deuterated saturated carbonyl compounds
spiked into smoking and nonsmoker breath samples described above. The recovery
percentages of formaldehyde, acetaldehyde, acetone and 2-butanone, hydroxyacetaldehyde
and 3-hydroxy-2-butanone in breath samples of nonsmokers are obviously higher that in
breath samples of smokers. However, the recovery percentages of unsaturated carbonyl
compounds in smoker’s breath samples were slightly higher than that in the breath samples
of nonsmokers. The concentrations of some carbonyl compounds including acetaldehyde,
formaldehyde, acetone and 2-butanone, hydroxyacetaldehyde in breath of cigarette
smokers are much higher than that in breath of nonsmokers.135-137 The stability differences
of carbonyl compounds in breath of smokers and nonsmokers are probably caused by
higher concentrations of these compounds and other VOCs in breath of smokers produced
in cigarette smoking.
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Figure 3.5 The relationship between the residual percentage and storage time of carbonyl
compounds under refrigerated cold temperature storage (4°C) of 7 smokers’ and 15
nonsmokers’ breath samples. (a)Formaldehyde and Acetaldehyde, (b)Acrolein and
crotonaldehyde, (c)Hydroxyacetaldehyde and 3-hydroxy-2-butanone, (d)acetone and 2butanone, (e) 4-HHE and 4-HNE.
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4. Conclusion
The recovery percentages of carbonyl VOCs in breath samples stored at cold
temperature (4 oC) are higher than that stored at room temperature. Breath samples are
recommended to be stored at cold temperature and to be processed in 2 hours to recover
above 80% of carbonyl compounds. Unsaturated aldehydes degrade much faster than
saturated carbonyl compounds. The long term stability tests indicate that the recovery
percentages of saturated carbonyl in breath samples stored at cold temperature can be above
50% for two day while unsaturated aldehydes decrease to less than 40% within only one
day. The recovery percentages of saturated carbonyl compounds in the breath samples of
smokers are obviously lower than that in the breath samples of nonsmokers.
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CHAPTER IV

ANALYSIS OF CARBONYL COMPOUNDS IN EXHALED BREATH USING THE
MICROREACTOR

1. Introduction
Lung cancer (LC) is one of the most frequently diagnosed cancers in the world and
is the leading causes of death worldwide, with more than 1 million deaths worldwide every
year due to its late diagnosis and the ineffectiveness of treatment for locally advanced and
metastatic disease. The fact that there are few symptoms during the early stages and those
appearing during advanced stages may be not specific which caused the delayed diagnosis.
All of this attracted a considerable interest in finding methods of diagnosis during the early
stages. The World Health Organization classification recognizes 20 different types of
malignant lung neoplasms.141,142 Non-small cell LC (NSCLC) and small-cell LC (SCLC)
represent two major forms of LC disease. NSCLC is subdivided into three major histologic
subtypes: adenocarcinoma, squamous-cell carcinoma, and large-cell carcinoma. It was
reported that SCLC and squamous-cell carcinoma are most strongly linked with smoking
while adenocarcinoma is the most common type of lung cancer in patients who have never
smoked.143
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The growing use of computed tomography (CT) has considerably increased the number of
incidentally detected small lung nodules, especially after recent publications showing that
low-dose CT for lung cancer screening in heavy former smokers and current smokers
increase 20% of lung cancer patient survival rate.

144,145

However, CT screening of lung

cancer is not specific which causes 94% of false positive prediction and a significant
number of subjects with falsely positive radiological results undergo unnecessary invasive
diagnostic approaches, including surgical resection although imaging techniques have
increased the frequency of diagnosis.146 In practice, due to consolidated protocols, imaging
techniques can reduce the number of false negatives while the positive predictive value
remains. False positive subjects will undergo unnecessary invasive diagnostic
interventions.147,148 Figure 4.1 shows a schematic diagram of the lung and its pathway to
produce the VOCs.

Figure 4.1 Schematic diagram of lung and its pathway to produce VOCs.
About 50% of subjects undergoing CT in European trials had pulmonary nodules;
20% of the subjects with pulmonary nodules were required specific management and 1-2%
were invasively treated, leading to a false positive rate of 50-60%.149,150 So it has been
suggested that diagnostic procedures, for example, CT scans, may lead to an excess risk of
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cancer due to radiation.151 In this situation, an inexpensive and non-invasive test with good
accuracy is required to identify high and low risk subjects.
An emerging approach for diagnosing early lung cancer or other lung diseases relies
on measuring volatile organic compounds (VOCs). It is well known that breath gas
contains different volatile organic compounds, furthermore, lung cancer-related changes
of VOCs are documented. The cancer cell formation and growth is accomplished by
immunity system changes that can lead to emit different volatile organic compounds
implicated the oxidative stress and peroxidation of the cell membrane species. There is a
significant difference with the concentrations of VOCs in exhaled breath between healthy
controls and lung cancer patients. By analysis of exhaled breath of lung cancer patients,
researchers found that some volatile organic compounds can serve as biomarkers of lung
cancer. 152-154
As of now, smoking is a strong lung cancer (LC) risk factor and plays an important
role in the carcinogenesis of cells in lung and affects the immunological activity and
metabolic procedure.155 How smoking affects the body will be studied by detecting the
exhaled VOCs from nonsmokers and smokers with different smoking behaviors. Recently
a lot of researchers proved that tobacco smoking is a major risk factor for lung cancer.156,157
Cigarette smoking is a mixture of more than 5000 chemical compounds, more than 60 are
recognized to have a specific carcinogenic potential.158 With the number of cigarettes
smoked per day and the years of smoking, there is a high risk to have lung disease. For
non-smoking people, exposure to secondhand smoke also increases the risk of lung cancer.
Most of the studies reported analyzed VOCs using gas chromatography mass
spectrometry (GC-MS). GC-MS is a powerful system which enables analysis of VOCs
93

qualitatively and quantitatively, however, it needs a long time to analyze the sample and
requires skilled operators. Solid phase microextraction–gas chromatography mass
spectrometry (SPME-GCMS) analysis also has been used to identify exhaled breath
biomarkers of lung cancer. But SPME also has some disadvantages, the surface area of
SPME polymer extraction phase is small.
The MEMS based microreactor has been successfully proved for capture of trace
level carbonyl compounds with high capture efficiency. There are thousands of
micropillars in the microreactors to distribute the gas flow. It also has a large surface area
for capturing the target VOCs. In this chapter, we use microreactors which have been
described before for quantitative analysis of trace carbonyls in exhaled breath.
2. Breath Samples and Study Population
Smoking can cause many lung diseases, for example, chronic obstructive
pulmonary disease (COPD), emphysema and lung cancer. Tobacco smoking will have a
large effect on exhaled breath when we analyze VOCs in it. Some other diseases such as
asthma and heart disease can also affect the VOCs in our breath. To find the difference in
breath samples between smoker group and non-smoker group for future identification of
carbonyl markers of lung cancer, a total of 107 healthy subjects, 47 current smokers (CS)
and 60 never smokers (NS) free from chronic lung disease or respiratory tract infection in
the age from 25 to 80 were recruited to provide exhaled breath samples in this study, after
approval by the Internal Review Board (IRB) at the university of Louisville and after
having obtained written informed consent from the subjects.
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2.1.Breath sampling and detection
Each volunteer breathed normally to fill a 1L Tedlar bag by directly breathe into
the air sampling bags through the attached Teflon tube. A mixed alveolar and tidal breath
is collected. The Tedlar bag was directly connected to the silicon microreactor through
deactivated silica tubes and septa as shown in Figure 4.3. Then, the vacuum pump forced
gaseous breath in Tedlar bags flowing through the fabricated microreactor at a fixed flow
rate of 3.5 ml/min. Figure 4.2 shows photos of a microreactor compared to a dime dollar,
SEM picture of triangular shape micropillars and microscopy photo of a microreactor.
Figure 4.3 shows a schematic setup for preconcentration of all carbonyl compounds in
breath samples by the silicon microreactor. The microreactor length is 7mm. There are
thousands of micropillars in the microreactor which were functionalized by a quaternary
ammonium aminooxy, ATM salt for capture of all carbonyl compounds by oximation
reactions. The unreacted ATM and reacted ATM adducts were eluted from the
microreactor by flowing 150µL methanol from one slightly pressurized vial through the
microreactor and then into an empty collecting sample vial. The eluted solutions were
directly used for FT-ICR-MS analysis without any further process. A 5 µL solution
containing 5 × 10

-9

mole of acetone-d6 completely reacted with ATM in methanol was

added to each eluted methanol solution as an internal reference for FTICR-MS analysis in
order to determine the concentrations of the carbonyl compounds in exhaled breath samples.
The amount of captured carbonyl compounds was determined by using a calibration curve.
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(a)

(b)

(c)

Figure 4.2 (a) One microreactor compared with quarter coin, (b) Optical picture of
fabricated microreactor and (c) SEM picture of micropillar arrays.

Figure 4.3 Schematic flow diagram of the preconcentration setup for breath analysis.
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2.2.Statistical analysis
The carbonyl VOC concentrations in exhaled breath sample of current smokers and
never smokers were measured by FTICR-MS. Figure 4.4 shows an example spectrum of
current smokers and never smokers. In order to further find out the difference between
these two groups, a Wilcoxon test was applied. The Wilcoxon test can be used for
comparing two related samples to assess whether their population means differ when the
population cannot be assumed to be normally distributed (p<0.05 was regarded as
significant).
2.3.Breath analysis of patients recruited for CT screening of lung cancer
After approved by the Internal Review Board at University of Louisville in
Kentucky and after having obtained written informed consent, exhaled breath samples of
117 patients, of them, 47 patients with pulmonary nodules, 70 without pulmonary nodules
and 9 patients with COPD were collected and analyzed. All patients were recruited from a
CT screening of early lung cancer program at Floyd Memorial Hospital. 107 healthy
subjects, 47 current smokers (CS) and 60 never smokers (NS) described above were used
as healthy control (HC) group. Table 4.1 shows the study population distribution of the
subjects.
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Table 4. 1
Subject information
Subjects

*

M/T*

Age(mean±SD)

Smoking History
Current

Former

Never

pulmonary nodules

17/47

62.25±7.25

20

19

8

Without nodules

32/70

64.2±7.45

9

50

11

COPD

2/9

64.2±7.45

2

6

1

Asthma

1/8

60.5±7.28

3

3

2

Healthy controls

35/107

58.25±12.27

47

0

60

M/T = the ratio of male subjects to total subjects

3. Results and Discussion
3.1 Detection of carbonyl compounds in smokers and nonsmokers
Tables 4.2-4.4 show the concentration ranges, median, mean and standard deviation
(SD) value of compounds for both healthy never smoker and smoker control groups. After
ANOVA test, Formaldehyde (p=0.000), Acetaldehyde (p=0.012) and Acetone (p<0.0001)
show a significant higher concentration for smokers in comparison with nonsmokers.
Figure 4.5 shows boxplots of concentrations of these three compounds in exhaled breath
samples from current and never smokers. The results imply that formaldehyde,
acetaldehyde and acetone are significantly affected by cigarette smoke, which may be
because there are residuals of these three compounds in the lungs of smokers.
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Table 4. 2
Concentration ranges and medians values of 60 never smokers and 47 current smokers
(nmol/L)
VOCs

Formaldehyd
e
CH2O

Acetaldehyde
C2H4O

0.117-0.439
(0.296)
0.205-2.165
(0.621)

0.27-2.70
(0.72)
0.23-3.67
(1.33)

Acetone
C3H6O

2-Butanone
C4H8O

3-Hydroxy2-butanone
C4H8O2

Pentanone
& pentanal
C5H10O

0.25-2.45
(1.95)
0.45-2.78
(1.78)

0.022-0.157
(0.075)
0.023-0.188
(0.09)

0.28-1.59
(0.75)
0.06-1.77
(0.78)

Sample
Never
smokers
Current
smokers

1.39-11. 2
(2.16)
2.15-16.98
(6.44)

Table 4. 3
Mean and SD values of 60 never smokers (NS) and 47 current smokers (CS) (nmol/L)
VOCs

Formaldehyd
e
CH2O

Acetaldehyde
C2H4O

0.267±0.06
1.18±0.25

1.258±0.27
1.921±0.31

Acetone
C3H6O

2-Butanone
C4H8O

3-Hydroxy2-butanone
C4H8O2

Pentanone
& pentanal
C5H10O

1.12±0.21
1.25±0.25

0.067±0.01
0.078±0.02

0.98±0.1
1.15±0.15

Sample
NS
CS

4.21±0.57
8.35±0.69
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Table 4. 4
Concentration ranges, medians and mean±SD values of 60 never smokers (NS) and 47
current smokers (CS) (nmol/L)
VOCs

Hydroxyacetaldehyde
C2H4O2

4-HHE
C2H4O

4-HNE
C3H6O

Acrolein
C4H8O

Sample
Never
Smokers

0.007-0.296
(0.092)
0.123±0.09

0-2.67×10-5
(7.37×10-5)
0.00098±0.0023

0-0.00035
(0.0004)
0.0398±0.1383

0-0.1162
(0.011)
0.022±0.033

Current
smokers

0.025-0.857
(0.204)
0.209±0.164

0-0.00383
(0.00099)
0.00177±0.0021

0-0.317
(0.00341)
0.0181±0.066

0-0.215
(0)
0.0204±0.05

100

Figure 4.4 Typical FTICR-MS spectra of breath samples. (a) Current smoker, and (b)
Never smoker. The peak of ATM is 2-(aminooxy)-N, N, N-trimethylethanammonium
cations. The peak of IR is internal reference ATM-acetone-d6. All other peaks are ATM
reacted with carbonyl VOCs. For example: ATM-C1H2O is ATM reacted with
formaldehyde and ATM-C2H4O is ATM reacted with acetaldehyde.
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Figure 4.5 Comparisons of three compounds from never smokers (NS) group(n=60) and
current smokers (CS) healthy control groups (n=47). (a) Formaldehyde, (b) Acetaldehyde,
(c) Acetone.
3.2.Detection of the carbonyl compounds in patients for CT screening of lung cancer
Fourteen carbonyl compounds were also found in exhaled breath samples and their
concentrations were determined. They are CH2O, C2H4O, C3H6O, C3H4O, C4H8O, C5H10O,
102

C6H12O, C7H14O, C8H16O, C9H18O, C10H20O, C2H4O2, C3H4O2, C4H8O2. After analysis of
exhaled breath samples of pulmonary nodule patients groups, without pulmonary nodules
groups and healthy controls groups, C3H6O (p=0.018), C2H4O2 (p=0.002) and C4H8O2
(p=0.009) were found to have statistical significance between the pulmonary nodule group
and HC group. C2H4O2 (p=0.001) and C4H8O (p=0.003) was found to have significantly
higher concentrations in pulmonary nodule group than these without nodules. Figure 4.6
shows boxplots of the concentrations of four compounds between pulmonary nodule group,
without pulmonary nodule group and HC group.
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Figure 4.6 Comparisons of carbonyl compounds from healthy control (HC, n=107) group,
pulmonary nodule (n=47) and without pulmonary (n=70) group. (a) C3H6O, (b) C2H4O2,
(c) C4H8O2 and (d) C4H8O.

According to the World Health Organization estimations, chronic obstructive
disease (COPD) will become the third leading cause of death worldwide by 2030.159-161
The types and concentrations of the detected VOCs can reflect the pathophysiological
changes in human body and be linked to a specific disease, including COPD. Among the
117 patients at Floyd Hospital, 9 patients were with COPD. After conducting ANOVA test
between healthy control and COPD patients, C2H4O2 (p=0.005) and C4H8O2 (p=0.008)
were found have significant difference. For C4H8O2 (p=0.008), there is a statistically
significant higher concentrations for COPD patients and thus can be used to discriminate
COPD patients from healthy controls while C2H4O2 (p=0.005) shows a significant lower
concentration for COPD patients when compared to healthy controls. Figure 4.7 shows
boxplots of the concentrations of the 2 compounds in exhaled breath samples from COPD
patients, healthy controls and smoker patients without benign pulmonary nodules. The
ANOVA test shows that there is no significant difference between smoker patients without
benign pulmonary nodules, healthy controls and COPD patients.
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Figure 4.7 Comparisons of carbonyl compounds from healthy control (HC, n=107) group,
COPD (n=9) group and smoker patients without benign pulmonary nodules (SWN, n=17)
group. (a) C2H4O2, (b) C4H8O2.
Asthma and chronic obstructive pulmonary disease (COPD) are widespread
respiratory diseases involving airway inflammation. Asthma is a chronic inflammation of
the airways that involves airflow obstruction and increased airway responsiveness to a
variety of stimuli.162,163 A key feature is the inflammation in both proximal and distal lung
airways. Although asthma affects people of all ages, it often starts in childhood. Asthma is
a growing medical problem with its incidence increasing in recent years. Among the 117
patients at Floyd Hospital, 8 patients were with asthma patients. By doing the ANOVA test,
we found three compounds CH2O (p=0.003), C2H4O (p=0.000) and C4H8O2 (p=0.000)
have significant higher concentrations than healthy control group. Therefore, CH2O,
C2H4O and C4H8O2 were chosen as the markers of asthma for diagnosis purpose. Figure
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4.8 shows the boxplots of three compounds CH2O, C2H4O and C4H8O2 between healthy
control group and asthma patients group.
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Figure 4.8 Comparisons of carbonyl compounds from healthy control (HC, n=107) group,
asthma group (n=8). (a) CH2O, (b) C2H4O, (c) C4H8O2.
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Since tobacco smoking and involuntary smoking are well documented in the
scientific literature to cause cancer. It is also known that smoking cigarettes increases the
amount of free radicals in human body. So, it is important for us to learn the smoking effect
in breath. Of all the 117 subjects collected from Floyd hospital, it was separated into three
groups: 19 never smokers, 69 former smokers and 29 current smokers. The criteria for
former smokers is subjects without smoking for more than 2 days. The other smoker
subjects were treated as current smokers. All patients were asked to fill in a questionnaire
describing their current smoking status, for example, active smokers, non-smokers, passive
smokers and the time elapsed since their last smoke. The classification to the appropriate
group was done on the basis self-declaration of the volunteers. The exhaled breath was
collected in 1L Tedlar bags which were cleaned by flushing with nitrogen gas. Then the
microreactor method was used to evacuate the samples followed by a FTICR-MS analysis.
Using ANOVA test, we found three carbonyl compounds (formaldehyde, acetaldehyde and
acetone) were significant change among these groups. Figure 4.9 shows the boxplots of
concentrations of the three identified compounds in exhaled breath samples from never
smoker (NS) group, former smoker (FS) group and current smoker (CS) group.
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Figure 4.9 Comparisons of carbonyl compounds from never smoker patients (n=19) group,
former smoking patients (n=69) and current smokers (n=29) groups. (a) CH2O, (b) C2H4O,
(c) C3H6O.

To further demonstrate the tobacco smoking will have a high effect on exhaled
breath. We further separate the 29 current smokers into two subgroups. 20 subjects just
smoked within 2 hours, 5 subjects did not smoke more than 4 hours but less than 2 days
and 4 subjects did not smoke more than 2 days as former smokers (FS). After conducting
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same ANOVA test, Formaldehyde (p=0.017), Acetaldehyde (p=0.001) and Acetone
(p=0.042) were also found to be significant higher in JS group than CS group. Figure 4.10
shows the boxplots of this situation.
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Figure 4.10 Comparisons of carbonyl compounds from current smoker (CS) group without
smoking for more than 4 hours (n=5), former smoker (FS) without smoking for more than
2 days (n=4) and smoke within 2 hours (JS) group (n=20). (a) CH2O, (b) C2H4O, (c) C3H6O.
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This study demonstrates the potential of MEMS based microreactors combined
with FTICR-MS system to identify breath markers for the distinction of subjects with
benign pulmonary nodules from healthy controls. Also, the patients with COPD and asthma
from healthy controls. The significant differences in concentrations of these certain
compounds in exhaled breath are related to metabolic differences of different types of lung
diseases. The data analysis in this study did not require complicated biostatistics models.
The biostatistics study in this research imply that breath test can be capable of detection of
lung diseases.
There are several advantages for this microreactor study. The microreactors are
designed to have high capture efficiencies of all carbonyl compounds. The ATM reaction
with carbonyl compounds through oximation reactions enables to analyze carbonyl
compounds related to biochemical metabolites. There is also one limition for FTICR-MS
which it is not able to identify untargeted components of a breath mixture, although it
provides accurate chemical formula. The microreactor method is noninvasive and
inexpensive. It does not require trained staff for their use and analysis. The microreactor
system can also be loaded with other chemical or physical adsorbent to capture other VOCs
in exhaled breath. The eluted analytes can be analyzed by gas chromatography-mass
spectrometry or proton transfer reaction mass spectrometry to satisfy the need to explain
the metabolism mechanism of VOCs in breath.
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4. Conclusion
This study shows that smoking history effects on exhaled breath. The concentration
ranges of formaldehyde, acetaldehyde and acetone for current smoking subjects are much
higher than those who did not smoke. The increasing number of carbonyl compounds in
the exhaled breath from smokers was caused by smoking cigarette. The study between
current smokers and smokers who just smoked within two hours further shows that
smoking can increase formaldehyde, acetaldehyde and acetone concentrations in exhaled
breath. The study between healthy controls, patients with pulmonary nodules and patients
without pulmonary nodules show that C3H6O, C2H4O2 and C4H8O2 can serve as biomarkers
to distinguish patients with pulmonary nodules from healthy controls. C2H4O2 and C4H8O
and serve as biomarkers for distinguish patients with pulmonary nodules from patients
without pulmonary nodules. For COPD, we found that C2H4O2 and C4H8O2 can serve as
biomarkers to identify them. Also, CH2O, C2H4O2 and C4H8O2 are good biomarkers that
distinguish asthma from healthy controls.
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CHAPTER V

DETECTION OF LUNG CANCER FROM EXHALED BREATH USING THE
MICROREACTOR

1. Introduction
Lung cancer is one of the leading causes of death in the world and can be classified
into two main types—non-small cell lung cancer (NSCLC) and small cell lung cancer
(SCLC). Most lung cancer patients are diagnosed at an advanced stage when the symptoms
(i.e., dyspnea, cough, fatigue, pain in thorax) appear and this often leads to poor prognosis.
The most effective treatment for lung cancer currently is pulmonary surgical resection,
however, the 5-year survival rate after surgical resection of stage ш patients is only 30%
while stage Ι patients show up to 70%.164,165 Therefore, earlier detection of lung cancer is
the key to increase patient survival rates. Various diagnosis tools for lung cancer such as
chest x-ray, chest computed tomography (CT) scan, bronchoscopy, fluorodeoxyglucosepositron emission tomography (FDG-PET) and lung biopsy are applied. However, the
existing diagnostic procedures are invasive, expensive and inaccurate. Currently, low-dose
CT screening is adopted for early detection of lung cancer but the false positive prediction
is too high (96%). Recent years, more and more researchers proposed exhaled breath
analysis can be used to detect lung cancer. There is strong evidence that molecular analysis
of exhaled breath can be used to detect particulate cancers.166-168 Breath analysis represent
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a new diagnostic technique that is commonly thought without risk for the patient even if
repeated frequently and it can provide information beyond conventional analysis of blood
and urine.

169-171

Even patients at an intensive care unit or during surgery it can still be

applied with. 172,173
There are novel cancer biomarkers in exhaled breath for lung cancer patients.
Various volatile organic compounds are contained in breath gas. Exhaled VOCs can
originate from two main sources; exogenous volatiles that are inhaled and then exhaled and
those endogenously produced by different biochemical processes through basic cellular
functions.174
Most of the studies reported analyzed VOCs using gas chromatography mass
spectrometry (GC-MS).175-177Although GC-MS is a powerful system which enables
analysis of VOCs qualitatively and quantitatively, it also has some disadvantages, for
example, it is high cost, time consuming and requires skilled operators.178 Biomarkers from
lung cancer patients are hard to define although many different VOCs are detected from
human exhaled breath by GC-MS. In this study, we used a microreactor system for
analyzing VOCs from exhaled breath to detect early stage lung cancer. A UHPLC-MS was
used to analyze the breath samples.
2. Breath Analysis of Lung Cancer Patient
2.1. Test population
After approval by the Internal Review Board at the University of Louisville in
Kentucky and after having obtained written informed consent, exhaled breath samples of
15 patients with untreated LC, 7 patients with benign pulmonary nodules (BN) and 15
113

healthy controls were collected and analyzed. All patients with pulmonary nodules were
recruited in the James Graham Brown Cancer Center at the University of Louisville.
Wilcoxon test was applied to identify specific VOCs as lung cancer markers from the
clinically diagnosed lung cancer subjects in comparison with healthy controls. All subjects
were patients with pulmonary nodules to be diagnosed at the time of collection of exhaled
breath samples. The concentration ranges of these VOCs markers were determined for
healthy controls, patients with cancer. Then these VOC markers were used to diagnose
cancer for all other breath analysis results. A diagnostic conclusion was made based on the
concentration levels of the specific VOCs. The diagnostic conclusions from breath analysis
were late confirmed by the clinical diagnosis. The general sample information is listed in
Table 5.1.
Table 5. 1
Subject information
Subjects

*

M/T*

Age(mean±SD)

Smoking History
Current

Former

Never

Lung cancers

12/15

64.22±9.1

6

6

3

Benign nodules

2/7

52.45±14.6

3

2

2

Healthy controls

7/15

52.21±15.1

7

2

6

M/T = the ratio of male subjects to total subjects

2.2. Breath sampling and detection
Each volunteer breathed normally to fill two Tedlar bags, the two Tedlar bags were
connected to a two-way switch valve. The first Tedlar bag is 600 mL and second Tedlar
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bag is 400 mL. The 600 mL is tidal breath and 400mL is alveolar breath. 3L (21mm) length
microreactors with triangular micropillars were used to evacuated breath samples. Figure
5.1 shows a SEM photo of the microreactor with triangular micropillars. After collection,
the Tedlar bags were directly connected to the silicon microreactor through deactivated
silica tubes and septa as shown in Figure 5.2. Then, a vacuum pump was used to force
gaseous breath in Tedlar breath flowing through the microreactor at a flow rate of 7mL/min.
Figure 5.2 shows a schematic setup for preconcentration of all carbonyl compounds in
breath samples by the silicon microreactor. A quaternary ammonium aminooxy compound,
ATM salt for capture of all carbonyl compounds by oximation reactions was coated on the
surface of thousands of micropillars in the microreactor. After evacuation, unreacted ATM
and reacted ATM adducts were eluted from the microreactor by flowing 200 µL methanol.
The eluted solutions were directly used for UHPLC-MS system analysis without any
further process. To determine the concentrations of the carbonyl compounds, a 5 μL
solution containing 5 × 10−9 mole of acetone-d6 completely reacted with ATM in methanol
was added to each eluted methanol solution as an internal reference for UHPLC-MS
analysis.
One of the most important advantages of UHPLC-MS compared to FT-ICR-MS is
that the UHPLC-MS has the ability to separate ketone and aldehyde with same molecular
formula. Figure 5.3 shows examples of separation results of mixtures of 2-butanone and
butanal, 2-pentanone and pentanal in the same solution. Also, another advantage is that
UHPLC-MS system is more sensitive and accurate than FT-ICR-MS.
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Figure 5.1 A SEM picture of the triangular micropillars inside the microreactor and the
photo of the microreactor compared to a dime dollar.

Figure 5.2 Schematic flow diagram of the preconcentration setup for breath analysis.

116

Figure 5.3 UHPLC-MS spectrum separation of 2-butanone and butanal, pentanal and 2pentanone.
3. Results and Discussion
3.1. Detection of the markers and Statistical analysis
The measured carbonyl VOC concentrations in exhaled breath sample of current
smokers and never smokers from healthy controls were fist separated and analyzed.
ANOVA test was applied to determine statistically significant differences between the
groups. After ANOVA test, Formaldehyde (p=0.013), acetaldehyde (p=0.002) and acetone
(p=0.036) presented significant higher concentrations for smokers in comparison with
nonsmokers. Figure 5.6 shows boxplots of the concentrations of three compounds in
exhaled breath samples from never smokers and current smokers.
Furthermore, we separate the lung cancer patients into three groups: current
smokers, previous smokers and never smokers. This statistical was designed to see whether
there is same effect of smoking when a person has lung cancer. Also, all the data was input
into Minitab software and conduct ANOVA test, after ANOVA test, formaldehyde,
acetaldehyde and acetone in current smoker’s lung cancer patients group have significant
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increase compared to lung cancer patients with previous smokers and never smokers. There
are significant differences between the lung cancer patients with never smokers and current
smokers (p<0.05) with the formaldehyde, acetaldehyde and acetone. Figure 5.7 shows the
boxplots of the concentrations of three compounds in exhaled breath samples from lung
cancer patients with never smokers, current smokers and previous smokers.
Twenty carbonyl compounds (CH2O, C2H4O, C3H6O, C3H4O, C4H8O, C5H10O,
C6H12O, C7H14O, C8H16O, C9H18O, C10H20O, C11H22O, C12H24O, C13H26O, C2H4O2,
C3H4O2, C4H8O2, C5H8O, C7H11O and C12H22O) were detected in exhaled breath samples
from lung cancer patients and healthy controls and their concentrations were determined.
Figure 5.4 shows a typical UHPLC-MS spectrum under MS mode with lung cancer patient
and healthy control. It can clearly see from the figure that most of the compounds detected
in lung cancer patient are higher than that in healthy control. After AVOVA test of exhaled
breath samples from the clinically diagnosed lung cancer subjects, C4H8O (p=0.022),
C4H8O2 (p=0.037) and 4-HNE (p=0.016) were found to have statistical significance
between the LC group and the HC group. Figure 5.5 shows the UHPLC-MS
chromatographs of these three compounds in lung cancer patient and healthy control. 4HHE (p=0.098) and Hydroxyacetaldehyde (p=0.100) was also found have considerable
difference between lung cancer group and healthy control group. Here our standard for
defining the significant difference is p<0.05. However, there is no significant difference in
concentrations of these lung cancer markers between BN patients and HC. Figure 5.8
shows the boxplots of the eight compounds between HC group, LC group and BN group.
The concentration of C4H8O and C4H8O2 in LC group was significantly higher than that in
HC group while concentration of 4-HNE in LC group was significantly lower than HC
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group. Therefore, C4H8O, C4H8O2 and 4-HNE were chosen as the biomarkers of lung
cancer for diagnosis purpose. 4-HHE and hydroxyacetaldehye (p<0.1) also have a
considerable difference between lung cancer and healthy control, but since our criteria here
for ANOVA test is p<0.05. We do not choose these two compounds for lung cancer
biomarkers. Table 5.2 shows the concentration ranges of these marker compounds in
exhaled breath of lung cancer patients, benign nodule patients and healthy controls. Simple
rules were made from the concentration ranges for lung cancer diagnosis: if 2 or more
marker concentrations are in the lung cancer range (including the overlap area), the subject
was assigned as lung cancer patient; otherwise the subject was considered as patient with
benign pulmonary nodules.
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Figure 5.4 Typical UHPLC-MS spectrum with mass mode between lung cancer patient and
healthy control.
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Figure 5.5 Typical UHPLC-MS chromatography between lung cancer patient and healthy
control. (a) 2-butanone, (b) 3-Hydroxy-2-butanone and (c) 4-HNE.
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Figure 5.6 Comparisons of three compounds from never smokers (NS, n=6) and healthy
control current smokers (CS, n=7) groups. (a) formaldehyde, (b) acetaldehyde and (c)
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Table 5. 2
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A comparison of identified lung cancer marker concentration range, mean and SD for
three different groups of people. (the second line of each row is median number)

LC

BN

HC

C4H8O

Mean±SD C4H8O2

Mean±SD 4-HNE

Mean±SD

(nmol/L)

(nmol/L)

(nmol/L)

(nmol/L)

(nmol/L)
0.002±0.003

(nmol/L)

0.748-5.37 1.94±1.17

0.178-1.78 0.45±0.39

1×10-5-1.5×10-3

(1.767)

(0.338)

(0.001029)

0.79-3.25

1.32±0.81

0.05-0.82

0.24±0.25
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Figure 5.8 Comparisons of compounds with HC group (n=15), LC group (n=15) and BN
group (n=7). (a) C4H8O, (b) C4H8O2, (c) 4-HNE, (d) 4-HHE, (e) C2H4O2, (f) C3H6O, (g)
CH2O and (h) C2H4O.
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3.2. Lung cancer type analysis
To further determine the capability of identifying and characterizing lung cancer
using these identified carbonyl VOC markers, the subjects were grouped into squamous
cell NSCLS and adenocarcinoma NSCLC. After conducting ANOVA test, 4-HNE was
found significant difference between squamous cell NSCLC and adenocarcinoma NSCLC
(p=0.03). (As shown in Figure 5.9)

Concentration (nmol/L)

0.020

0.015

0.010

0.005

0.000
Adeno

Squamous

Figure 5.9 Comparisons of 4-HNE with adenocarcinoma NSCLC (n=9) and squamous cell
NSCLC (n=6).
4. Conclusion
This study demonstrates the potential of MEMS based microreactors combined
with UHPLC-MS system to identify lung cancer breath markers for the distinction of
subjects with lung cancer from subjects with healthy controls. The results show that
UHPLC-MS has advantages of separation and sensitivity on carbonyl VOCs compared to
FT-ICR-MS. The results also show that breath markers can discriminate between lung
cancer of different types. The significant differences in concentrations of these identified
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markers in exhaled breath are related to metabolic differences of different types of lung
cancers. This research demonstrated a fabricated silicon microreactor chip of 21mm length
with triangular micropillars for preconcentration and analysis of carbonyls compounds in
exhaled breath. We have found three VOCs (2-butanone, 3-hydroxy-2-butanone and 4HNE) to distinguish LC from patients with benign pulmonary nodules and healthy controls,
particularly 4-HNE can also be used to distinguish squamous cell carcinoma from
adenocarcinoma LC. The 4-HHE and Hydroxyacetaldehyde do not considered as markers
for lung cancer here since p>0.05, but they are very promising since p<0.1.
However, the test population in this study is relatively small, since this is an
ongoing project, we are still collecting more patients subjects from Brown Cancer Center.
Once we get enough subjects, for examples, different stages and types of lung cancer
patients, benign pulmonary nodule patients and healthy controls. We will do statistical
analysis

can

potentially find

more

biomarkers

(especially for

4-HHE

and

Hydroxyacetaldehyde) that can be used to distinguish different stages of lung cancer
patients.
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CHAPTER VI

SUMMARY AND FUTURE WORK

This research demonstrated MEMS based microreactors coated with aminooxy
compounds combined with UHPLC-MS for chemoselective capture and analysis of trace
level aldehydes and ketones. Sample sources include human exhaled breath and ambient
air.

1. Summary
We have successfully designed a novel silicon-based microreactor with thousands
of micropillars. The fabrication procedure follows the MEMS microfabrication techniques
and fabricated at Micro/Nano Technology Center in University of Louisville.
The silicon-based microreactor coated with the aminooxy reagent ATM as a
derivatization reagent (coating) to capture trace level carbonyl compounds was
comprehensively characterized. Different designs of the microreactor were generated by
L-edit software. For example, 3 different pillar distance (10 µm, 25µm and 50 µm), four
different micropillar shapes (cylindrical, square, triangle and diamond) and five different
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microreactor length (7mm, 14mm, 21mm, 28mm and 42mm). The study shows that when
under the same microreactor length, the design with 10µm micropillar distance and triangle
pillar shape has the best performance in capture trace aldehydes and ketones. The capture
efficiency can achieve 95% at a gaseous flow rate less than 8 ml/min.
The microreactors with different length were then intensively studied in this
research. 7mm, 14mm, 21mm, 28mm and 42mm length microreactors were all loaded same
amount of ATM since the loading effect study in chapter 2 shows the different amount of
ATM has almost no effect on capture efficiencies. The experimental results show that the
microreactor capture efficiencies of trace carbonyls decrease with the increasing of flow
rate. For a certain flow rate range (<10ml/min), there is no significant capture efficiency
difference between the 21mm, 28mm and 42mm microrractors. Considering the practical
application and economical thought, 21mm length microreactor with 10µm and triangle
shape micropillars is the optimal microreactor for capture of trace levels carbonyls in
human exhaled breath. A theoretical model was then developed for modeling the
microreactor gas reactions. Both mass transfer limiting aspect and reaction rate limiting
aspect were discussed. The comparison between the experimental data and model data
show that the model fit the reaction very well.
This method was used for investigating the stability of human exhaled breath
including smokers and nonsmokers. The results show that the recovery percentages of
carbonyl VOCs in breath samples stored at cold temperature (4 oC) are higher than that
stored at room temperature. Unsaturated aldehydes degrade much faster than saturated
carbonyl compounds. The recovery percentages of saturated carbonyl compounds in the

130

breath samples of smokers are obviously lower than that in the breath samples of
nonsmokers.
This microreactor technology can be applied for analyzing any gas phase samples
and also for environmental monitoring of volatile organic compounds whose
concentrations are at ppb levels.
This method was also used to identify breath markers for the distinction of subjects
with pulmonary nodules from healthy controls and the patients with COPD and asthma
from healthy controls for pilot lung cancer screening project. C3H6O, C2H4O2 and C4H8O2
was found can serve as biomarkers to distinguish the patients with pulmonary nodules from
healthy people. Smokers and nonsmokers also were found to have significant different in
acetaldehyde, formaldehyde and acetone ranges. In the clinical study with lung cancer
patients, we found three VOCs (2-butanone, 3-hydroxy-2butanone and 4-HNE) to
distinguish LC from healthy controls. One VOC (4-HNE) to distinguish squamous cell
carcinoma from adenocarcinoma LC.
2. Future Directions
There are several areas or directions in the near future, which we could further
enhance the work presented in this dissertation.
1. A study with a larger study population is necessary to validate the biomarkers of
lung cancer patients and patients with pulmonary nodules that we found in this work.
For examples, different stages of lung cancer patients, follow up study with lung
cancer patients. Also, more patients with benign pulmonary nodules need to be
collected.
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2. In this study, only aminooxy salt was used as the coating materials in microreactors
to capture specific carbonyl VOCs. Other compounds may also be used to coat on
the micropillar to capture these compounds. Also, specific catalyst may also load
into the surface on the micropillars or inside the microreactor to help trigger and
accelerate the selected reaction in order to get more effective analysis, especially to
reduce the analysis time to several minutes.
3. The metabolism mechanism of VOCs in lung cancer patients’ breath is still not
known in this study. One effective way is that to analyze the VOCs released by
lung cancer cells which are cultured in clinical stations. For example, the headspace
air in lung cancer cell line and culture solution.
4. One limitation od this study is that an aminooxy coated microreactor can only
identify or detect the carbonyl compounds components of analytical samples with
accurate chemical formula, it can not identify other components of the sample like
dienes, furans, alcohols, ether etc. Other method need to be developed to analyze
more compounds.
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